<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ESMO Open</journal-id><journal-id journal-id-type="iso-abbrev">ESMO Open</journal-id><journal-id journal-id-type="hwp">esmoopen</journal-id><journal-id journal-id-type="publisher-id">esmoopen</journal-id><journal-title-group><journal-title>ESMO Open</journal-title></journal-title-group><issn pub-type="epub">2059-7029</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27843622</article-id><article-id pub-id-type="pmc">5070302</article-id><article-id pub-id-type="publisher-id">esmoopen-2016-000062</article-id><article-id pub-id-type="doi">10.1136/esmoopen-2016-000062</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group></article-categories><title-group><article-title>Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>K&#x000fc;mler</surname><given-names>Iben</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Knoop</surname><given-names>Ann S</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jessing</surname><given-names>Christina A R</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ejlertsen</surname><given-names>Bent</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>Dorte L</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Oncology</addr-line>, <institution>Herlev Hospital, University of Copenhagen</institution>, <addr-line>Herlev</addr-line>, <country>Denmark</country></aff><aff id="af2"><label>2</label><addr-line>Department of Oncology</addr-line>, <institution>Finsen Centre, Rigshospitalet, University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country></aff><author-notes><corresp><label>Correspondence to</label> Iben K&#x000fc;mler; <email>iben.kumler@regionh.dk</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>16</day><month>8</month><year>2016</year></pub-date><volume>1</volume><issue>4</issue><elocation-id>e000062</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2016</year></date><date date-type="rev-recd"><day>12</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="esmoopen-2016-000062.pdf"/><abstract><sec><title>Background</title><p>Endocrine therapy constitutes a central modality in the treatment of oestrogen receptor (ER)-positive advanced breast cancer.</p></sec><sec><title>Purpose</title><p>To evaluate the evidence for endocrine treatment in postmenopausal patients with advanced breast cancer focusing on the aromatase inhibitors, letrozole, anastrozole, exemestane and fulvestrant.</p></sec><sec><title>Methods</title><p>A review was carried out using PubMed. Randomised phase II and III trials reporting on &#x02265;100 patients were included.</p></sec><sec><title>Results</title><p>35 trials met the inclusion criteria. If not used in the adjuvant setting, a non-steroid aromatase inhibitor was the optimal first-line option. In general, the efficacy of the different aromatase inhibitors and fulvestrant was similar in tamoxifen-refractory patients. A randomised phase II trial of palbociclib plus letrozole versus letrozole alone showed significantly increased progression-free survival (PFS) when compared with endocrine therapy alone in the first-line setting (20.2 vs 10.2&#x02005;months). Furthermore, the addition of everolimus to exemestane in the Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) study resulted in an extension of median PFS by 4.5&#x02005;months after recurrence/progression on a non-steroid aromatase inhibitor. However, overall survival was not significantly increased.</p></sec><sec><title>Conclusion</title><p>Conventional treatment with an aromatase inhibitor or fulvestrant may be an adequate treatment option for most patients with hormone receptor-positive advanced breast cancer. Mammalian target of rapamycin (mTOR) inhibition and cyclin-dependent kinase 4/6 (CDK4/6) inhibition might represent substantial advances for selected patients in some specific settings. However, there is an urgent need for prospective biomarker-driven trials to identify patients for whom these treatments are cost-effective.</p></sec></abstract><kwd-group><kwd>Advanced breast cancer,</kwd><kwd>Endocrine therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Breast cancer is strongly related to age. The highest incidence rates are found in older, postmenopausal women. Approximately 70&#x02013;80% of breast cancers are oestrogen and/or progesterone receptor (ER/PGR) positive and, thus, potentially sensitive to endocrine therapy.<xref rid="R1" ref-type="bibr">1</xref></p><p>After menopause, about 90% of the total body oestrogens are synthesised by aromatisation of androstenedione into oestrone, and the production may be blocked by aromatase inhibitors (AIs). The first AI with documented antitumour efficacy was aminoglutethimide. Following this, second-generation and third-generation AIs have been developed. The third-generation inhibitors including letrozole, anastrozole and exemestane have increased potency associated with better clinical efficacy compared with aminoglutethimide or the second-generation inhibitor fadrazole.<xref rid="R2" ref-type="bibr">2</xref> Pharmacologically, AIs may be subdivided into two classes: non-steroidal AI (NSAI) represented by letrozole and anastrozole, and steroidal AI (SAI) represented only by exemestane. Both groups of AIs block aromatase activity: NSAIs inhibit the aromatase in a reversible manner by binding to the haem moiety of the enzyme, thus preventing androgens from binding to the catalytic site. SAIs bind covalently to the substrate binding site of the aromatase, irreversibly inactivating the enzyme.<xref rid="R2" ref-type="bibr">2</xref> Apart from AIs, endocrine treatment consists of the selective ER modulator (SERM) tamoxifen and the pure antioestrogen fulvestrant. Tamoxifen has mixed agonistic and antagonistic activity, depending on the target tissue. In contrast, fulvestrant is a complete ER antagonist which in addition introduces a conformational change leading to monomers degrading ER,<xref rid="R3" ref-type="bibr">3&#x02013;5</xref> theoretically overcoming resistance driven by the agonist properties of tamoxifen.</p><p>The purpose of this review was to evaluate outcome in clinical trials performed in postmenopausal patients with advanced breast cancer treated with various endocrine regimens, including letrozole, anastrozole, exemestane and fulvestrant.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>No review protocol exists. However, before initiating the review, we decided on a search strategy in which PubMed was searched for human studies using the &#x02018;clinical trial&#x02019; filter and the following search terms: AI, endocrine therapy and advanced/metastatic breast cancer. In addition, we searched for the specific drugs. Papers from 1980 and onwards were included. In total, 535 articles were identified. Subsequently, we applied the following exclusion criteria: phase I and non-randomised phase II trials, dose-finding studies, studies on first-generation or second-generation AIs, trials including &#x0003c;100 patients, studies reporting on various antihormonal treatments in which it was not possible to distinguish between the different outcomes, preclinical studies and reviews. Articles on exploratory subgroup analyses and studies evaluating the compounds in premenopausal women or including premenopausal and postmenopausal patients were also excluded. Fully published, randomised phase II or III trials in English were included. Full articles were obtained and references were checked for additional material when appropriate. The reference list was updated in October 2015.</p><p>Two authors (IK and DLN) independently surveyed the literature. In case of unclarity, a verdict was reached by consensus.</p></sec><sec sec-type="results" id="s3"><title>Results</title><p>A total of 35 trials were included in the present review.</p><sec id="s3a"><title>Studies comparing AIs or fulvestrant with an antioestrogen, megestrol acetate or a first-generation AI</title><p>In total, 11 trials were identified, including 1 phase II&#x02013;III and 10 phase III trials. Results are presented in <xref ref-type="table" rid="ESMOOPEN2016000062TB1">table 1</xref>.</p><table-wrap id="ESMOOPEN2016000062TB1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><p>Summary of randomised phase II and III studies comparing third-generation aromatase inhibitors or fulvestrant with an antioestrogen, megestrol acetate or a first-generation aromatase inhibitor</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Treatment*</th><th align="left" rowspan="1" colspan="1">Number of patients</th><th align="left" rowspan="1" colspan="1">Patient population</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Prior endocrine therapy</th><th align="left" rowspan="1" colspan="1">Prior chemotherapy for ABC</th><th align="left" rowspan="1" colspan="1">RR (%) (95% CI)</th><th align="left" rowspan="1" colspan="1">SD (%) (95% CI)</th><th align="left" rowspan="1" colspan="1">TTP/PFS (median; months) (95% CI)</th><th align="left" rowspan="1" colspan="1">OS (median; months) (95% CI)</th></tr></thead><tbody><tr><td colspan="11" rowspan="1"><italic>First-line therapy</italic></td></tr><tr><td colspan="11" rowspan="1">NSAIs vs tamoxifen</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Bonneterre <italic>et al</italic><xref rid="R6" ref-type="bibr">6</xref>
<xref rid="R8" ref-type="bibr">8</xref></td><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">340</td><td rowspan="2" colspan="1">ER/PGR+ (UK 54/56%)</td><td rowspan="2" colspan="1">III (TARGET)</td><td rowspan="2" colspan="1">None: 89/88%; &#x0003e;12&#x02005;months adj TAM: 11/12%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">32.9</td><td rowspan="1" colspan="1">23.2</td><td rowspan="1" colspan="1">8.2; ER/PGR+: 8.9</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Tamoxifen</td><td rowspan="1" colspan="1">328</td><td rowspan="1" colspan="1">32.6</td><td rowspan="1" colspan="1">22.9</td><td rowspan="1" colspan="1">8.3 (p=0.941); ER/PGR+: 7.8</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Nabholtz <italic>et al</italic><xref rid="R7" ref-type="bibr">7</xref>
<xref rid="R9" ref-type="bibr">9</xref></td><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">171</td><td rowspan="2" colspan="1">ER+ (UK 11/11%)</td><td rowspan="2" colspan="1">III (NAT)</td><td rowspan="2" colspan="1">None: 82/79%; &#x0003e;12&#x02005;months adj TAM: 18/21%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">38.0</td><td rowspan="1" colspan="1">11.1</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Tamoxifen</td><td rowspan="1" colspan="1">182</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">28.6</td><td rowspan="1" colspan="1">5.6 (p=0.005)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Milla-Santos <italic>et al</italic><xref rid="R10" ref-type="bibr">10</xref></td><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">121</td><td rowspan="2" colspan="1">ER+</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">18.0</td><td rowspan="1" colspan="1">17.4</td></tr><tr><td rowspan="1" colspan="1">Tamoxifen 40&#x02005;mg</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">26 (p=0.172)</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">7.0 (HR 0.13; p&#x0003c;0.01)</td><td rowspan="1" colspan="1">16.0 (HR 0.64; p=0.003)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Mouridsen <italic>et al</italic><xref rid="R12" ref-type="bibr">12&#x02013;14</xref></td><td rowspan="1" colspan="1">Letrozole</td><td rowspan="1" colspan="1">453</td><td rowspan="2" colspan="1">ER/PGR+ (UK 34/33%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None: 81/82% &#x0003e;12&#x02005;months adj TAM: 19/18%</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">49 (44 to 54) (CBR)</td><td rowspan="1" colspan="1">9.4</td><td rowspan="1" colspan="1">34</td></tr><tr><td rowspan="1" colspan="1">Tamoxifen</td><td rowspan="1" colspan="1">454</td><td rowspan="1" colspan="1">20 (OR 1.71; 1.26 to 2.31; p=0.0006)</td><td rowspan="1" colspan="1">38 (34 to 43)</td><td rowspan="1" colspan="1">6.0 (p=0.0001)</td><td rowspan="1" colspan="1">30 (p=0.53)</td></tr><tr><td colspan="11" rowspan="1">SAI vs tamoxifen</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Paridaens <italic>et al</italic><xref rid="R15" ref-type="bibr">15</xref>
<xref rid="R16" ref-type="bibr">16</xref></td><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">182</td><td rowspan="2" colspan="1">Hormone receptor+ (UK 8/5%)</td><td rowspan="2" colspan="1">II/III</td><td rowspan="2" colspan="1">None: 79/61%; &#x0003e;6&#x02005;months adj TAM: 21/21%</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">29.7&#x02020;</td><td rowspan="1" colspan="1">9.9 (8.7 to 11.8)</td><td rowspan="2" colspan="1">p=0.821</td></tr><tr><td rowspan="1" colspan="1">Tamoxifen</td><td rowspan="1" colspan="1">189</td><td rowspan="1" colspan="1">31 (OR 1.85; 1.21 to 2.82; p=0.005)</td><td rowspan="1" colspan="1">35.4</td><td rowspan="1" colspan="1">5.8 (5.3 to 8.1) (HR 0.84; p=0.121)</td></tr><tr><td colspan="11" rowspan="1">Fulvestrant vs tamoxifen</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Howell 2004 <italic>et al</italic><xref rid="R17" ref-type="bibr">17</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg</td><td rowspan="1" colspan="1">313</td><td rowspan="2" colspan="1">ER/PGR+ (UK 18/20%; ER&#x02212;/PGR&#x02212; 1/1%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None: 78/75%; &#x0003e;12&#x02005;months adj TAM: 22/25%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">31.8</td><td rowspan="1" colspan="1">54.3&#x02020; (CBR)</td><td rowspan="1" colspan="1">6.8</td><td rowspan="1" colspan="1">36.9 (estimated)</td></tr><tr><td rowspan="1" colspan="1">Tamoxifen</td><td rowspan="1" colspan="1">274</td><td rowspan="1" colspan="1">33.9 (OR 0.87; 0.61 to 1.24; p=0.45)</td><td rowspan="1" colspan="1">62.0 (p=0.026)</td><td rowspan="1" colspan="1">8.3 (HR 1.18; p=0.088)</td><td rowspan="1" colspan="1">38.7 (HR 1.29; p=0.04)</td></tr><tr><td colspan="11" rowspan="1"><italic>First-line or second-line therapy</italic></td></tr><tr><td colspan="11" rowspan="1">NSAIs vs megestrol acetate</td></tr><tr><td rowspan="3" colspan="1">&#x02003;Buzdar <italic>et al</italic><xref rid="R18" ref-type="bibr">18</xref></td><td rowspan="1" colspan="1">Anastrozole 1&#x02005;mg</td><td rowspan="1" colspan="1">128</td><td rowspan="3" colspan="1">ER+ or prior sensitivity to TAM (UK 13/15/13%)</td><td rowspan="3" colspan="1">III</td><td rowspan="3" colspan="1">PD on antioestrogen&#x02021;; adj antioestrogen: 47/42/39%</td><td rowspan="3" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">5.6</td><td rowspan="3" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole 10&#x02005;mg</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">4.7</td></tr><tr><td rowspan="1" colspan="1">Megestrol acetate</td><td rowspan="1" colspan="1">128</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="3" colspan="1">&#x02003;Jonat <italic>et al</italic><xref rid="R19" ref-type="bibr">19</xref></td><td rowspan="1" colspan="1">Anastrozole 1&#x02005;mg</td><td rowspan="1" colspan="1">135</td><td rowspan="3" colspan="1">ER/PGR+ (UK 34/39/38%)</td><td rowspan="3" colspan="1">III</td><td rowspan="3" colspan="1">PD after/on TAM; adj TAM: 49/39 /42%; first-line TAM: 51/61/58%</td><td rowspan="3" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">34.1</td><td rowspan="1" colspan="1">34.0 (CBR)</td><td rowspan="3" colspan="1">NR</td><td rowspan="3" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole 10&#x02005;mg</td><td rowspan="1" colspan="1">118</td><td rowspan="1" colspan="1">33.9</td><td rowspan="1" colspan="1">33.9</td></tr><tr><td rowspan="1" colspan="1">Megestrol acetate</td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">32.8</td><td rowspan="1" colspan="1">32.8</td></tr><tr><td rowspan="3" colspan="1">&#x02003;Buzdar <italic>et al</italic><xref rid="R21" ref-type="bibr">21</xref></td><td rowspan="1" colspan="1">Letrozole 0.5&#x02005;mg</td><td rowspan="1" colspan="1">202</td><td rowspan="3" colspan="1">ER/PGR+ (UK 13/15/13%)</td><td rowspan="3" colspan="1">III</td><td rowspan="3" colspan="1">PD on antioestrogen&#x02021;; adj antioestrogen: 47/42/39%; first-line antioestrogen: 53/58/61%</td><td rowspan="3" colspan="1">&#x02264;2</td><td rowspan="1" colspan="1">21 (15.2 to 26.4)</td><td rowspan="1" colspan="1">12.4</td><td rowspan="1" colspan="1">5.6 (3.3 to 6.3)</td><td rowspan="1" colspan="1">33.1 (26.7 to 39.4)</td></tr><tr><td rowspan="1" colspan="1">Letrozole 2.5&#x02005;mg</td><td rowspan="1" colspan="1">199</td><td rowspan="1" colspan="1">16 (11.0 to 21.2)</td><td rowspan="1" colspan="1">10.6</td><td rowspan="1" colspan="1">3.2 (3.0 to 5.3)</td><td rowspan="1" colspan="1">26.6 (25.0 to 33.8)</td></tr><tr><td rowspan="1" colspan="1">Megestrol acetate</td><td rowspan="1" colspan="1">201</td><td rowspan="1" colspan="1">15 (10.0 to 19.9)</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">3.4 (3.0 to 5.6)</td><td rowspan="1" colspan="1">26.2 (21.7 to 29.9)</td></tr><tr><td rowspan="3" colspan="1">&#x02003;Dombernowsky <italic>et al</italic><xref rid="R22" ref-type="bibr">22</xref></td><td rowspan="1" colspan="1">Letrozole 0.5&#x02005;mg</td><td rowspan="1" colspan="1">188</td><td rowspan="3" colspan="1">ER/PGR+ (UK 45/43/41%)</td><td rowspan="3" colspan="1">III</td><td rowspan="3" colspan="1">PD on antioestrogen&#x02021;; adj antioestrogen: 35/33/32%</td><td rowspan="3" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">13 (p=0.004)</td><td rowspan="1" colspan="1">14.4</td><td rowspan="1" colspan="1">5.1 (p=0.02)</td><td rowspan="1" colspan="1">1.34 (risk ratio)</td></tr><tr><td rowspan="1" colspan="1">Letrozole 2.5&#x02005;mg</td><td rowspan="1" colspan="1">174</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">10.9</td><td rowspan="1" colspan="1">5.6 (p=0.07)</td><td rowspan="1" colspan="1">0.82</td></tr><tr><td rowspan="1" colspan="1">Megestrol acetate</td><td rowspan="1" colspan="1">189</td><td rowspan="1" colspan="1">16 (p=0.04)</td><td rowspan="1" colspan="1">15.3</td><td rowspan="1" colspan="1">5.5</td><td rowspan="1" colspan="1">1.12</td></tr><tr><td colspan="11" rowspan="1">SAI vs megestrol acetate</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Kaufmann <italic>et al</italic><xref rid="R23" ref-type="bibr">23</xref></td><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">366</td><td rowspan="2" colspan="1">ER/PGR+ (UK+or prior sensitivity to TAM (UK 33/32%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">PD on TAM&#x02021;; adj TAM: NR</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">37.4 (CBR)</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">Not reached</td></tr><tr><td rowspan="1" colspan="1">Megestrol acetate</td><td rowspan="1" colspan="1">404</td><td rowspan="1" colspan="1">012.4 (NS)</td><td rowspan="1" colspan="1">34.6 (NS)</td><td rowspan="1" colspan="1">3.7 (p=0.037)</td><td rowspan="1" colspan="1">27.4(p=0.039)</td></tr></tbody></table><table-wrap-foot><fn><p>For RR, SD, duration of TTP/PFS and OS, the number of decimals reported by the authors is given.</p></fn><fn><p>ER/PGR+, HER2: numbers are given when possible.</p></fn><fn><p>*Unless stated, doses of tamoxifen, megestrol acetate, anastrozole, letrozole and exemestane were 20, 160, 1, 2.5 and 25&#x02005;mg, respectively.</p></fn><fn><p>&#x02020;Duration of SD not reported; if not marked, duration of SD reported &#x02265;24&#x02005;weeks or 6&#x02005;months.</p></fn><fn><p>&#x02021;Defined as relapse on adjuvant antioestrogen or within 12&#x02005;months of stopping treatment or progression on first-line antioestrogen therapy.</p></fn><fn><p>ABC, advanced breast cancer; Adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; NR, not reported; NS, non-significant; NSAI, non-steroid aromatase inhibitor; PD, progressive disease; PFS, progression-free survival; PGR, progesterone receptor; RR, response rate; SAI, steroid aromatase inhibitor; TAM, tamoxifen; TARGET, Tamoxifen or &#x02018;Arimidex&#x02019; Randomized Group Efficacy and Tolerability; TTP, time to progression; OS, overall survival; UK, unknown.</p></fn></table-wrap-foot></table-wrap><sec id="s3a1"><title>First-line therapy</title><sec id="s3a1a"><title>NSAIs versus tamoxifen</title><p>Three phase III studies compared anastrozole with tamoxifen as first-line therapy. The Tamoxifen or &#x02018;Arimidex&#x02019; Randomized Group Efficacy and Tolerability (TARGET) trial including 668 women (43% known hormone receptor (HR) positive) found the two treatments to be equivalent regarding response rate (RR) and time to progression (TTP).<xref rid="R6" ref-type="bibr">6</xref> The North American Multicenter Randomized trial (NAT) trial included 353 patients among which almost 90% were HR positive. The RR was similar in the two arms; however, anastrozole had a significant advantage over tamoxifen in terms of a nearly doubling of TTP.<xref rid="R7" ref-type="bibr">7</xref> The two studies had a similar design and were prospectively planned for a combined analysis. Among all included patients, TTP was similar in the two groups. However, a subgroup analysis among HR-positive patients (&#x0223c;60%) revealed a TTP of 10.7&#x02005;months in the anastrozole group compared with 6.4&#x02005;months in the tamoxifen group (p=0.022). Median time to death was 40.8 and 41.3&#x02005;months, respectively.<xref rid="R8" ref-type="bibr">8</xref>
<xref rid="R9" ref-type="bibr">9</xref> Crossover was not preplanned in these studies.</p><p>A third trial in ER-positive, hormonal therapy-na&#x000ef;ve patients showed significant advantage of anastrozole regarding clinical benefit rate (CBR), TTP and median time to death.<xref rid="R10" ref-type="bibr">10</xref></p><p>The P025 trial of letrozole versus tamoxifen in 907 patients showed superiority of letrozole, regarding RR and TTP. The findings were irrespective of prior adjuvant antioestrogen treatment.<xref rid="R11" ref-type="bibr">11</xref>
<xref rid="R12" ref-type="bibr">12</xref> The overall survival (OS), however, was not statistically different.<xref rid="R13" ref-type="bibr">13</xref> Approximately half of the patients in each arm crossed over to the other agent on progression. Thus, OS results might have been confounded. Indeed, a planned statistical analysis 2&#x02005;years after randomisation showed a 62% vs 57% survival in the letrozole and tamoxifen group, respectively (p=0.0246).<xref rid="R14" ref-type="bibr">14</xref></p></sec><sec id="s3a1b"><title>SAI versus tamoxifen</title><p>A phase II/III trial comparing exemestane with tamoxifen showed an increased RR after exemestane and early significant differences in progression-free survival (PFS) (Wilcoxon p=0.028). However, this early finding did not translate into a significant benefit in PFS or OS.<xref rid="R15" ref-type="bibr">15</xref>
<xref rid="R16" ref-type="bibr">16</xref></p></sec><sec id="s3a1c"><title>Fulvestrant (250&#x02005;mg) versus tamoxifen</title><p>A phase III non-inferiority trial including 587 patients compared fulvestrant (250&#x02005;mg) with tamoxifen. Approximately 78% of the patients were HR positive and &#x0223c;25% had received adjuvant tamoxifen prior to inclusion. Overall RR and TTP were not significantly different. In addition, a prospectively planned analysis of patients with known HR-positive status showed equal efficacy of the drugs. Estimated OS was 36.9&#x02005;months in the fulvestrant group and 38.7&#x02005;months in the tamoxifen group (HR 1.29; p=0.04).<xref rid="R17" ref-type="bibr">17</xref> In the subgroup of patients who had received adjuvant tamoxifen, the results were similar to those of the whole population.</p></sec></sec><sec id="s3a2"><title>First-line or second-line therapy</title><sec id="s3a2a"><title>NSAIs versus megestrol acetate</title><p>Two phase III trials compared two doses of anastrozole with megestrol acetate in patients who had progressed after tamoxifen. RRs were comparable and no significant difference between the two anastrozole regimens and megestrol acetate regarding TTP and OS on an initial analysis was found.<xref rid="R18" ref-type="bibr">18</xref>
<xref rid="R19" ref-type="bibr">19</xref> However, a planned subsequent analysis found anastrozole 1&#x02005;mg to be associated with significantly increased OS compared with megestrol acetate (26.7 vs 22.5&#x02005;months; p&#x0003c;0.025).<xref rid="R20" ref-type="bibr">20</xref></p><p>Two different doses of letrozole were compared with megestrol acetate as second-line therapy in women previously treated with antioestrogen in two phase III trials. The first study included 602 women (80&#x02013;85% HR positive). RR was not significantly different among the three treatment regimens. However, patients treated with letrozole 0.5&#x02005;mg had a significantly longer TTP (5.6 vs 3.4&#x02005;months) and a decreased risk of treatment failure compared with patients treated with megestrol acetate. Letrozole 0.5&#x02005;mg showed a trend (p=0.053) towards a survival benefit.<xref rid="R21" ref-type="bibr">21</xref> The second study included 551 patients. The RR was significantly higher for letrozole 2.5&#x02005;mg (24%) compared with letrozole 0.5&#x02005;mg (13%) or megestrol acetate (16%). TTP for letrozole 2.5&#x02005;mg was superior to letrozole 0.5&#x02005;mg, but not to megestrol acetate. There was a significant dose effect on OS in favour of letrozole 2.5&#x02005;mg (p=0.03) compared with letrozole 0.5&#x02005;mg. The OS was similar in the letrozole 2.5&#x02005;mg and megestrol acetate arms. However, letrozole was significantly better tolerated than megestrol acetate.<xref rid="R22" ref-type="bibr">22</xref></p></sec><sec id="s3a2b"><title>SAI versus megestrol acetate</title><p>A randomised phase II trial comparing exemestane with megestrol acetate in patients who had experienced tamoxifen failure showed significantly increased TTP and OS in favour of exemestane.<xref rid="R23" ref-type="bibr">23</xref></p></sec></sec></sec><sec id="s3b"><title>Studies comparing the individual AIs with each other or with fulvestrant, or combinations</title><p>A total of 12 trials were identified: one randomised phase II, nine phase III, one phase III&#x02013;IV and one study with combined data from two phase III trials. Efficacy results are given in <xref ref-type="table" rid="ESMOOPEN2016000062TB2">table 2</xref>.</p><table-wrap id="ESMOOPEN2016000062TB2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><p>Summary of randomised phase II and III studies comparing the individual aromatase inhibitors with each other, with fulvestrant, or combinations</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Treatment*</th><th align="left" rowspan="1" colspan="1">Number of patients</th><th align="left" rowspan="1" colspan="1">Patient population</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Prior endocrine therapy</th><th align="left" rowspan="1" colspan="1">Prior chemotherapy for ABC</th><th align="left" rowspan="1" colspan="1">RR (%) (95% CI)</th><th align="left" rowspan="1" colspan="1">SD (%) (95% CI)</th><th align="left" rowspan="1" colspan="1">TTP/PFS (median; months) (95% CI)</th><th align="left" rowspan="1" colspan="1">OS (median; months) (95% CI)</th></tr></thead><tbody><tr><td colspan="11" rowspan="1"><italic>First-line therapy</italic></td></tr><tr><td colspan="11" rowspan="1">Exemestane vs anastrozole</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Iwata <italic>et al</italic><xref rid="R24" ref-type="bibr">24</xref></td><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">149</td><td rowspan="2" colspan="1">ER/PGR+ (HER2&#x02212; 94/94%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None: 83/83%; &#x0003e;12&#x02005;months adj TAM: 17/17%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">43.8 (35.3 to 52.8)</td><td rowspan="1" colspan="1">31.1</td><td rowspan="1" colspan="1">13.8 (10.8 to 16.59</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">149</td><td rowspan="1" colspan="1">39.1 (30.6 to 48.1)</td><td rowspan="1" colspan="1">38.3</td><td rowspan="1" colspan="1">11.1 (10.8 to 16.6)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Llombart-Cussac <italic>et al</italic><xref rid="R25" ref-type="bibr">25</xref></td><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">51</td><td rowspan="2" colspan="1">ER/PGR+ (UK 0/4%)</td><td rowspan="2" colspan="1">II, randomised</td><td rowspan="2" colspan="1">None: 49/50%; &#x0003e;24&#x02005;months adj TAMs: 51/50%</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">36.2 (18.5 to 45.9)</td><td rowspan="1" colspan="1">59.6 (CBR)</td><td rowspan="1" colspan="1">6.1 (2.4 to 9.6)</td><td rowspan="1" colspan="1">19.9 (15.32 to 24.46)</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">46.0 (32.2 to 59.8)</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">12.1 (7.3 to 16.8) (HR 1.13; p=0.558)</td><td rowspan="1" colspan="1">48.3 (18.3 to 78.3) (HR 1.33; p=0.296)</td></tr><tr><td colspan="11" rowspan="1">Fulvestrant vs anastrozole</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Robertson <italic>et al</italic><xref rid="R26" ref-type="bibr">26</xref>
<xref rid="R27" ref-type="bibr">27</xref></td><td rowspan="1" colspan="1">Fulvestrant 500&#x02005;mg</td><td rowspan="1" colspan="1">102</td><td rowspan="2" colspan="1">ER/PGR+ (UK 1/3%) (HER2 2+/3+ 19/18%)</td><td rowspan="2" colspan="1">III (FIRST)</td><td rowspan="2" colspan="1">None: 72/78%; adj endocrine therapy: 28/22%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">31.4</td><td rowspan="1" colspan="1">41.2</td><td rowspan="1" colspan="1">23.4</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">103</td><td rowspan="1" colspan="1">31.1</td><td rowspan="1" colspan="1">35.0</td><td rowspan="1" colspan="1">13.1 (HR 0.66; p=0.01)</td></tr><tr><td colspan="11" rowspan="1">Combination therapy vs single agent</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Bergh <italic>et al</italic><xref rid="R28" ref-type="bibr">28</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg+anastrozole</td><td rowspan="1" colspan="1">258</td><td rowspan="2" colspan="1">ER/PGR+</td><td rowspan="2" colspan="1">III (FACT)</td><td rowspan="2" colspan="1">None: 30/34%; adj TAM: 70/67%; adj AI: 2/1%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">31.8</td><td rowspan="1" colspan="1">55.0 (CBR)</td><td rowspan="1" colspan="1">10.8</td><td rowspan="1" colspan="1">37.8</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">256</td><td rowspan="1" colspan="1">33.6 (OR 0.92; p=0.76)</td><td rowspan="1" colspan="1">55.1 (OR 1.0; p=0.99)</td><td rowspan="1" colspan="1">10.2 (HR 0.99; p=0.91)</td><td rowspan="1" colspan="1">38.2 (HR 1.0; p=1.00)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Mehta <italic>et al</italic><xref rid="R29" ref-type="bibr">29</xref></td><td rowspan="1" colspan="1">Anastrozole+fulvestrant 250&#x02005;mg</td><td rowspan="1" colspan="1">349</td><td rowspan="2" colspan="1">ER/PGR+ HER2+ 10/9%</td><td rowspan="2" colspan="1">III (SWOG 0226)</td><td rowspan="2" colspan="1">None: 60/60%; &#x0003e;12&#x02005;months adj TAM: 40/40%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">73&#x02020;</td><td rowspan="1" colspan="1">15.0 (13.2 to 18.4)</td><td rowspan="1" colspan="1">47.7 (43.4 to 55.7)</td></tr><tr><td rowspan="1" colspan="1">Anastrozole &#x02192; fulvestrant (41%)</td><td rowspan="1" colspan="1">345</td><td rowspan="1" colspan="1">22 (p=0.26)</td><td rowspan="1" colspan="1">70 (p=0.39)</td><td rowspan="1" colspan="1">13.5 (12.1 to 15.1) (HR 0.80; p=0.007)</td><td rowspan="1" colspan="1">41.3 (37.2 to 45.0) (HR 0.81; p=0.049)</td></tr><tr><td colspan="11" rowspan="1"><italic>First-line or second-line therapy</italic></td></tr><tr><td colspan="11" rowspan="1">Letrozole vs anastrozole</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Rose <italic>et al</italic><xref rid="R30" ref-type="bibr">30</xref></td><td rowspan="1" colspan="1">Letrozole</td><td rowspan="1" colspan="1">356</td><td rowspan="2" colspan="1">ER/PGR+ (UK 21/8%)</td><td rowspan="2" colspan="1">IIIb/IV</td><td rowspan="2" colspan="1">PD&#x02021; on antioestrogen; adj antioestrogen: number NR</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">19.1 (15.7 to 22.9)</td><td rowspan="1" colspan="1">7.9</td><td rowspan="1" colspan="1">5.7 (5.1 to 6.0)</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">357</td><td rowspan="1" colspan="1">12.3 (9.6 to 15.6) (p=0.013)</td><td rowspan="1" colspan="1">10.6</td><td rowspan="1" colspan="1">5.7 (4.6 to 6.1) (p=0.92)</td></tr><tr><td colspan="11" rowspan="1">Fulvestrant vs AIs</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Howell <italic>et al</italic><xref rid="R31" ref-type="bibr">31</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg</td><td rowspan="1" colspan="1">222</td><td rowspan="2" colspan="1">ER/PGR+ or prior sensitivity to endocrine therapy (UK 23/16%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">PD on adj: 56/56%; PD on first-line endocrine therapy: 44/44% no prior AI</td><td rowspan="2" colspan="1">&#x02264;2</td><td rowspan="1" colspan="1">20.7</td><td rowspan="1" colspan="1">23.9</td><td rowspan="1" colspan="1">5.5</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">229</td><td rowspan="1" colspan="1">15.7</td><td rowspan="1" colspan="1">29.3</td><td rowspan="1" colspan="1">5.1</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Xu <italic>et al</italic><xref rid="R32" ref-type="bibr">32</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg+placebo</td><td rowspan="1" colspan="1">121</td><td rowspan="2" colspan="1">ER+</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">PD after adj: NR; PD on first-line antioestrogen therapy: NR</td><td rowspan="2" colspan="1">&#x02264;2</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">48.2&#x02020; (CBR)</td><td rowspan="1" colspan="1">3.6</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole+placebo</td><td rowspan="1" colspan="1">113</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">36.1 (OR 0.608; p=0.117)</td><td rowspan="1" colspan="1">5.2 (HR 1.314; p=0.101)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Robertson <italic>et al</italic><xref rid="R33" ref-type="bibr">33</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg+placebo</td><td rowspan="1" colspan="1">206</td><td rowspan="2" colspan="1">ER/PGR+ or prior sensitivity to endocrine therapy (UK 6/8%) (ER/PGR&#x02212; 7/5%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">PD on adj antioestrogen therapy: 56/50%; PD on first-line endocrine therapy: 44/50%</td><td rowspan="2" colspan="1">No criteria</td><td rowspan="1" colspan="1">17.5</td><td rowspan="1" colspan="1">24.8</td><td rowspan="1" colspan="1">5.4</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole+placebo</td><td rowspan="1" colspan="1">194</td><td rowspan="1" colspan="1">17.5</td><td rowspan="1" colspan="1">18.6</td><td rowspan="1" colspan="1">3.4 (HR 0.92; p=0.43)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Robertson <italic>et al</italic><xref rid="R33" ref-type="bibr">33</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg</td><td rowspan="1" colspan="1">428</td><td rowspan="2" colspan="1">ER/PGR+ or prior sensitivity to endocrine therapy (UK 15/12%) (ER/PGR&#x02212; 5/5%)</td><td rowspan="2" colspan="1">Combined data from two phase III (0020 and 0021)</td><td rowspan="2" colspan="1">PD after adj endocrine therapy: 57/56%; PD on first-line endocrine therapy: 43/44%</td><td rowspan="2" colspan="1">NR</td><td rowspan="1" colspan="1">19.2</td><td rowspan="1" colspan="1">24.3</td><td rowspan="2" colspan="1">NR</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">423</td><td rowspan="1" colspan="1">16.5 (p=0.32)</td><td rowspan="1" colspan="1">24.3</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Chia <italic>et al</italic><xref rid="R34" ref-type="bibr">34</xref></td><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg</td><td rowspan="1" colspan="1">351</td><td rowspan="2" colspan="1">ER/PGR+</td><td rowspan="2" colspan="1">III (EFECT)</td><td rowspan="2" colspan="1">PD on NSAI&#x02021;; 60% &#x02265;2 lines</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">7.4</td><td rowspan="1" colspan="1">32.2 (CBR)</td><td rowspan="1" colspan="1">3.7</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">342</td><td rowspan="1" colspan="1">6.7 (OR 1.12; p=0.736)</td><td rowspan="1" colspan="1">31.5 (OR 1.03; p=0.853)</td><td rowspan="1" colspan="1">3.7 (HR 0.963; p=0.6531)</td></tr><tr><td colspan="11" rowspan="1">Combination therapy vs single agent</td></tr><tr><td rowspan="3" colspan="1">&#x02003;Johnston <italic>et al</italic><xref rid="R35" ref-type="bibr">35</xref></td><td rowspan="1" colspan="1">Fulvestrant+anastrozole</td><td rowspan="1" colspan="1">243</td><td rowspan="3" colspan="1">ER/PGR+ HER2&#x02212; (HER2+ 7/6/7%) (HER2 UK 43/33/36%)</td><td rowspan="3" colspan="1">III (SoFEA)</td><td rowspan="3" colspan="1">PD on adj NSAI: 17/22/17% first-line NSAI: 83/78/83%</td><td rowspan="3" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">4.4 (3.4 to 5.4)</td><td rowspan="1" colspan="1">20.2 (17.2 to 22.5)</td></tr><tr><td rowspan="1" colspan="1">Fulvestrant+placebo</td><td rowspan="1" colspan="1">231</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">4.8 (3.6 to 5.5)</td><td rowspan="1" colspan="1">19.4 (16.8 to 22.8)</td></tr><tr><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">249</td><td rowspan="1" colspan="1">4 (NS)</td><td rowspan="1" colspan="1">23 (NS)</td><td rowspan="1" colspan="1">3.4 (3.0 to 4.6) (NS)</td><td rowspan="1" colspan="1">21.6 (19.4 to 23.9) (NS)</td></tr></tbody></table><table-wrap-foot><fn><p>For RR, duration of TTP/PFS and OS, the number of decimals used by the authors is reported. ER/PGR+, HER2: % positive are given when possible.</p></fn><fn><p>*Doses of anastrozole, letrozole and exemestane were 1, 2.5 and 25&#x02005;mg, respectively.</p></fn><fn><p>&#x02020;Duration of SD not reported; if not marked, duration of SD reported &#x02265;24&#x02005;weeks or 6&#x02005;months.</p></fn><fn><p>&#x02021;Defined as relapse on adjuvant NSAI or within 6&#x02005;months of stopping treatment or by progression on NSAI for advanced breast cancer.</p></fn><fn><p>ABC, advanced breast cancer; Adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; NR, not reported; NS, non-significant; NSAI, non-steroid aromatase inhibitor; PD, progressive disease; PFS, progression-free survival; PGR, progesterone receptor; RR, response rate; TAM, tamoxifen; TTP, time to progression; OS, overall survival; UK, unknown.</p></fn></table-wrap-foot></table-wrap><sec id="s3b1"><title>First-line therapy</title><sec id="s3b1a"><title>Exemestane versus anastrozole</title><p>One phase III trial compared exemestane with anastrozole in the first-line setting among 298 patients. RRs and TTP were identical in the two arms.<xref rid="R24" ref-type="bibr">24</xref> Likewise, a randomised phase II trial found the clinical activity of the two drugs to be equal.<xref rid="R25" ref-type="bibr">25</xref></p></sec><sec id="s3b1b"><title>Fulvestrant (500&#x02005;mg) versus anastrozole</title><p>The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) trial was a phase II trial comparing fulvestrant (500&#x02005;mg) with anastrozole as first-line treatment. Approximately 25% of the patients had received adjuvant endocrine therapy (the number of patients receiving an AI was not reported).<xref rid="R26" ref-type="bibr">26</xref>
<xref rid="R27" ref-type="bibr">27</xref> RR and CBR were comparable in the treatment arms; however, TTP was 23.4 and 13.1&#x02005;months, respectively, for fulvestrant and anastrozole, indicating superiority of fulvestrant to anastrozole in this setting. It should be noted that TTP was a secondary end point.</p></sec><sec id="s3b1c"><title>Combination therapy versus single agent</title><p>The Fulvestrant and Anastrozole Combination Therapy (FACT) trial compared fulvestrant+anastrozole with anastrozole in 514 women of whom approximately two-thirds had received adjuvant tamoxifen. TTP and OS were identical in the two arms.<xref rid="R28" ref-type="bibr">28</xref> The Southwest Oncology Group (SWOG) 0226 trial evaluated fulvestrant+anastrozole to anastrozole in 694 patients, of which &#x0223c;40% had received adjuvant tamoxifen. In the anastrozole monotherapy arm, crossover to fulvestrant after progression was strongly encouraged. The median PFS was 15.0&#x02005;months in the fulvestrant+anastrozole arm compared with 13.5&#x02005;months in the anastrozole arm followed by fulvestrant arm (p=0.007). OS was 47.7 and 41.3&#x02005;months, respectively (p=0.0049), despite the fact that 41% of patients crossed over to fulvestrant after progression.<xref rid="R29" ref-type="bibr">29</xref></p></sec></sec><sec id="s3b2"><title>First-line or second-line therapy</title><sec id="s3b2a"><title>Letrozole versus anastrozole</title><p>A phase IIIb/IV trial compared letrozole with anastrozole in patients who had progressed on first-line antioestrogen or were clinically resistant to adjuvant tamoxifen. TTP, the primary end point, was 5.7&#x02005;months in both arms. However, RR was significantly higher in the letrozole arm (19.1% vs 12.3%; p=0.013).<xref rid="R30" ref-type="bibr">30</xref></p></sec><sec id="s3b2b"><title>Fulvestrant (250&#x02005;mg) versus AIs</title><p>Four studies comparing fulvestrant (250&#x02005;mg) with anastrozole in the first-line or second-line setting were identified. All studies reported similar efficacy of the two drugs with regard to RR and TTP. No survival data were provided.<xref rid="R31" ref-type="bibr">31&#x02013;33</xref></p><p>The Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) trial compared fulvestrant (250&#x02005;mg) with exemestane in patients who had progressed on an NSAI. In 60% of women, the agents were administered as third or higher lines of therapy. No significant difference in efficacy parameters was found.<xref rid="R34" ref-type="bibr">34</xref></p></sec><sec id="s3b2c"><title>Combination therapy versus single agent</title><p>The Study of Faslodex with or without concomitant Arimidex vs Exemestane following progression on non-steroidal Aromatase inhibitors (SoFEA) trial compared fulvestrant (250&#x02005;mg)+anastrozole or placebo with exemestane monotherapy in the first-line or second-line setting. A total of 723 patients, previously progressing on an NSAI, were included. No statistically significant differences in outcome were found.<xref rid="R35" ref-type="bibr">35</xref></p></sec></sec></sec><sec id="s3c"><title>Studies of combinations of AI/fulvestrant and other drugs</title><p><xref ref-type="table" rid="ESMOOPEN2016000062TB3">Table&#x000a0;3</xref> shows efficacy results of AI/fulvestrant in combinations with other drugs. Nine trials were identified, including five randomised phase II and four phase III studies. Most studies were performed in the first-line or second-line setting including patients known to be HR positive. Human epidermal growth factor receptor 2 (HER2) status was known in many of the studies, some excluding HER2-positive patients.</p><table-wrap id="ESMOOPEN2016000062TB3" orientation="portrait" position="float"><label>Table&#x000a0;3</label><caption><p>Summary of randomised phase II and III trials of endocrine therapy combined with other agents in patients with hormone receptor-positive metastatic breast cancer</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Treatment*</th><th align="left" rowspan="1" colspan="1">Number of patient</th><th align="left" rowspan="1" colspan="1">Patient population</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Prior endocrine therapy</th><th align="left" rowspan="1" colspan="1">Prior chemotherapy for ABC</th><th align="left" rowspan="1" colspan="1">RR (%)</th><th align="left" rowspan="1" colspan="1">SD (%)</th><th align="left" rowspan="1" colspan="1">TTP/PFS (median; months) (95% CI)</th><th align="left" rowspan="1" colspan="1">OS (median; months) (95% CI)</th></tr></thead><tbody><tr><td colspan="11" rowspan="1">COX-2 inhibitor</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Dirix <italic>et al</italic><xref rid="R37" ref-type="bibr">37</xref></td><td rowspan="1" colspan="1">Exemestane+celecoxib</td><td rowspan="1" colspan="1">56</td><td rowspan="2" colspan="1">ER/PGR+ or prior sensitivity to hormone receptor therapy (UK 30/38%)</td><td rowspan="2" colspan="1">II, randomised</td><td rowspan="2" colspan="1">PD on TAM; adj TAM: 62/50%; first-line TAM: 38/50%; no prior AI</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">21.5</td><td rowspan="1" colspan="1">21.4</td><td rowspan="1" colspan="1">5.2</td><td rowspan="1" colspan="1">16.4</td></tr><tr><td rowspan="1" colspan="1">Exemestane</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">23.6</td><td rowspan="1" colspan="1">4.4</td><td rowspan="1" colspan="1">16.5</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Falandry <italic>et al</italic><xref rid="R36" ref-type="bibr">36</xref></td><td rowspan="1" colspan="1">Exemestane+celecoxib</td><td rowspan="1" colspan="1">74</td><td rowspan="2" colspan="1">ER/PGR+ (UK 7/6%) (HER2+ 4/5%)</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None: 43/39%; adj TAM: 57/61%; no prior AI</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">55&#x02020;</td><td rowspan="1" colspan="1">9.8</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Exemestane+placebo</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">17 (p=0.18)</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">9.8 (p=0.72)</td></tr><tr><td colspan="11" rowspan="1">mTOR inhibitor</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Baselga <italic>et al</italic><xref rid="R39" ref-type="bibr">39</xref>; Piccart <italic>et al</italic><xref rid="R40" ref-type="bibr">40</xref></td><td rowspan="1" colspan="1">Exemestane+everolimus</td><td rowspan="1" colspan="1">485</td><td rowspan="2" colspan="1">ER+HER2&#x02212;</td><td rowspan="2" colspan="1">III, BOLERO-2</td><td rowspan="2" colspan="1">Refractory NSAI&#x02021;; prior AI 100/100%; adj endocrine therapy: 28/28%; first-line endocrine therapy: 72/72%</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">7.0&#x02020;</td><td rowspan="1" colspan="1">74.6&#x000a7;</td><td rowspan="1" colspan="1">10.6&#x000a7;</td><td rowspan="1" colspan="1">31.0</td></tr><tr><td rowspan="1" colspan="1">Exemestane+placebo</td><td rowspan="1" colspan="1">239</td><td rowspan="1" colspan="1">0.4 (p&#x0003c;0.001)</td><td rowspan="1" colspan="1">64.4</td><td rowspan="1" colspan="1">4.1 (HR 0.36; p&#x0003c;0.001)</td><td rowspan="1" colspan="1">26.6 (p=0.14)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Wolff <italic>et al</italic><xref rid="R42" ref-type="bibr">42</xref></td><td rowspan="1" colspan="1">Letrozole+temsirolimus</td><td rowspan="1" colspan="1">555</td><td rowspan="2" colspan="1">ER+ (95/96%) HER2+ (18/23%)</td><td rowspan="2" colspan="1">III (HORIZON)</td><td rowspan="2" colspan="1">None: 57/60%; adj endocrine therapy: 43/40%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">27</td><td rowspan="2" colspan="1">NR</td><td rowspan="1" colspan="1">8.9 (7.4 to 9.6)</td><td rowspan="1" colspan="1">Not estimable</td></tr><tr><td rowspan="1" colspan="1">Letrozole+placebo</td><td rowspan="1" colspan="1">555</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">9.0 (7.2 to 9.4) (HR 0.90; p=0.25)</td><td rowspan="1" colspan="1">(HR 0.89; p=0.5)</td></tr><tr><td colspan="11" rowspan="1">HER1 inhibitor</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Carlson <italic>et al</italic><xref rid="R45" ref-type="bibr">45</xref></td><td rowspan="1" colspan="1">Anastrozole+gefitinib</td><td rowspan="1" colspan="1">72</td><td rowspan="2" colspan="1">ER/PGR +</td><td rowspan="2" colspan="1">II, randomised</td><td rowspan="2" colspan="1">None: 54/58%; adj endocrine therapy: 46/42%</td><td rowspan="2" colspan="1">&#x02264;2</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">5.3 (3.1 to 10.4)</td><td rowspan="1" colspan="1">30.3 (21.2 to 38.9+)</td></tr><tr><td rowspan="1" colspan="1">Fulvestrant 250&#x02005;mg+gefitinib</td><td rowspan="1" colspan="1">69</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">5.2 (2.9 to 8.2)</td><td rowspan="1" colspan="1">23.9 (15.4 to 33.5)</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Martin <italic>et al</italic><xref rid="R47" ref-type="bibr">47</xref></td><td rowspan="1" colspan="1">Letrozole/fulvestrant+bevacizumab</td><td rowspan="1" colspan="1">190</td><td rowspan="2" colspan="1">Hormone receptor+ HER2&#x02212;</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None:48/47%; adj endocrine therapy: 52/53%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">77 (CBR)</td><td rowspan="1" colspan="1">19.3 (16.5 to 22.1)</td><td rowspan="1" colspan="1">52.1</td></tr><tr><td rowspan="1" colspan="1">Letrozole/fulvestrant</td><td rowspan="1" colspan="1">184</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">14.4 (11.4 to 17.5) (HR 0.83; p=0.126)</td><td rowspan="1" colspan="1">51.8 (HR 0.87; p=0.518)</td></tr><tr><td colspan="11" rowspan="1">Histone deacetylase inhibitor</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Yardley <italic>et al</italic><xref rid="R48" ref-type="bibr">48</xref></td><td rowspan="1" colspan="1">Exemestane+entinostat</td><td rowspan="1" colspan="1">64</td><td rowspan="2" colspan="1">ER+</td><td rowspan="2" colspan="1">II, randomised</td><td rowspan="2" colspan="1">PD on NSAI&#x000b6;; adj endocrine therapy: 52/48%; first-line endocrine therapy: 84/86%</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">6.3</td><td rowspan="1" colspan="1">28.1&#x02020; (CBR)</td><td rowspan="1" colspan="1">4.3 (3.3 to 5.4)</td><td rowspan="1" colspan="1">28.1 (21.2- not reached)</td></tr><tr><td rowspan="1" colspan="1">Exemestane+placebo</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">4.6</td><td rowspan="1" colspan="1">25.8</td><td rowspan="1" colspan="1">2.3 (1.8 to 3.7) (HR 0.73; p=0.11)</td><td rowspan="1" colspan="1">19.8 (17.0 to 26.7) (HR 0.59; p=0.036)</td></tr><tr><td colspan="11" rowspan="1">Cyclin-dependent kinase 4/6 inhibitor</td></tr><tr><td rowspan="2" colspan="1">&#x02003; Finn <italic>et al</italic><xref rid="R49" ref-type="bibr">49</xref>
<xref rid="R50" ref-type="bibr">50</xref></td><td rowspan="1" colspan="1">Letrozole+palbociclib</td><td rowspan="1" colspan="1">84</td><td rowspan="2" colspan="1">ER+ HER2&#x02212;</td><td rowspan="2" colspan="1">II, randomised</td><td rowspan="2" colspan="1">None: 59/55%; adj TAM: 29/30%; adj AI: 12/15%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">10.2 (5.7 to 12.6)</td><td rowspan="2" colspan="1">Not powered for OS</td></tr><tr><td rowspan="1" colspan="1">Letrozole</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">20.2 (13.8 to 27.5) (p=0.0004)</td></tr><tr><td colspan="11" rowspan="1">Antiboby directed against MUC1</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Ibrahim <italic>et al</italic><xref rid="R52" ref-type="bibr">52</xref></td><td rowspan="1" colspan="1">Letrozole+anti-MUC1 antibody (AS1402)</td><td rowspan="1" colspan="1">56</td><td rowspan="2" colspan="1">ER/PGR HER2&#x02212;</td><td rowspan="2" colspan="1">II, randomised</td><td rowspan="2" colspan="1">None: 84/80%; &#x0003e;12&#x02005;months adj AI: 16/20%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">12.5</td><td rowspan="1" colspan="1">57.1&#x02020;</td><td rowspan="2" colspan="1">(HR 0.925)</td><td rowspan="2" colspan="1">NR</td></tr><tr><td rowspan="1" colspan="1">Letrozole</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">25.9</td><td rowspan="1" colspan="1">50.0</td></tr></tbody></table><table-wrap-foot><fn><p>For RR, duration of TTP/PFS and OS, the number of decimals used by the authors is reported.</p></fn><fn><p>ER/PGR+, HER2: % positive are given when possible.</p></fn><fn><p>*Doses of anastrozole, letrozole and exemestane were 1, 2.5 and 25&#x02005;mg, respectively.</p></fn><fn><p>&#x02020;Duration of SD not reported; if not marked, duration of SD reported &#x02265;24&#x02005;weeks or 6&#x02005;months.</p></fn><fn><p>&#x02021;Defined as recurrence during or &#x02264;12&#x02005;months after adjuvant NSAI or PD during or within 1&#x02005;month after treatment for advanced breast cancer.</p></fn><fn><p>&#x000a7;Central assessment.</p></fn><fn><p>&#x000b6;Defined as relapse after adjuvant therapy administered for &#x02265;12&#x02005;months or PD on NSAI for MBC administered for &#x02265;3&#x02005;months.</p></fn><fn><p>ABC, advanced breast cancer; Adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; COX-2, cyclooxygenase-2; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; NR, not reported; NSAI, non-steroid aromatase inhibitor; PD, progressive disease; PFS, progression-free survival, PGR, progesterone receptor; RR, response rate; TAM, tamoxifen; TTP, time to progression, OS, overall survival; UK, unknown.</p></fn></table-wrap-foot></table-wrap><sec id="s3c1"><title>COX-2 inhibitor</title><p>One phase II and one phase III trial evaluated the addition of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to exemestane versus exemestane alone. In both studies, patients were AI na&#x000ef;ve. None of the studies found significant differences in PFS.<xref rid="R36" ref-type="bibr">36</xref>
<xref rid="R37" ref-type="bibr">37</xref> Thus, the addition of celecoxib did not add any clinically relevant benefit to exemestane.</p></sec><sec id="s3c2"><title>mTOR inhibitors</title><p>Among other mechanisms, endocrine resistance has been attributed to the crosstalk between ER signalling and the phosphatidylinositol 3-kinase (PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)) pathway. Thus, dual targeting of both pathways may enhance efficacy of endocrine therapy.<xref rid="R38" ref-type="bibr">38</xref></p><p>The Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) study compared exemestane combined with the mTOR inhibitor everolimus with exemestane+placebo in patients previously treated with an NSAI. In total, 724 patients were randomised 2:1. No crossover was allowed. A significant difference in PFS was found favouring everolimus (10.6 vs 4.1&#x02005;months).<xref rid="R39" ref-type="bibr">39</xref>
<xref rid="R40" ref-type="bibr">40</xref> The trial was stopped early after a prespecified interim analysis found a significantly better PFS for the combination arm. However, OS was similar in the two arms.<xref rid="R40" ref-type="bibr">40</xref></p><p>A retrospective, exploratory subgroup analysis in patients whose last treatment was in the (neo)adjuvant setting showed a median PFS in the combination arm of 15.2 vs 4.2&#x02005;months in the exemestane+placebo arm; HR 0.32, 95% CI 0.18 to 0.57. Thus, the addition of everolimus nearly tripled PFS in the first-line setting.<xref rid="R41" ref-type="bibr">41</xref> In contrast, the Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (HORIZON) study comparing temsirolimus plus letrozole with letrozole failed to show any difference between treatment arms regarding PFS (9&#x02005;months in both groups) and OS.<xref rid="R42" ref-type="bibr">42</xref></p></sec><sec id="s3c3"><title>HER1-targeted therapy</title><p>Preclinical studies have suggested that activation of the epidermal growth factor receptor (EGFR) pathway might be an important mechanism of endocrine resistance.<xref rid="R43" ref-type="bibr">43</xref> Approximately 30% of HR-positive patients with breast cancer overexpress EGFR.<xref rid="R44" ref-type="bibr">44</xref></p><p>In a randomised phase II trial, anastrozole+gefitinib was compared with fulvestrant (250&#x02005;mg)+gefitinib. The RR, CBR and PFS did not differ for the two regimens. Median OS was 30.3&#x02005;months for anastrozole+gefitinib vs 23.9&#x02005;months for fulvestrant+gefitinib.<xref rid="R45" ref-type="bibr">45</xref> Thus, efficacy rates were not clearly superior to endocrine therapy alone.<xref rid="R46" ref-type="bibr">46</xref> Furthermore, the combinations had a less favourable safety profile compared with endocrine therapy.</p></sec><sec id="s3c4"><title>Angiogenesis inhibitors</title><p>Preclinical studies have shown that vascular endothelial growth factor (VEGF) induced proliferation in breast cancer cell lines by interfering with the actions of oestrogens. Only one randomised study was identified. In total, 374 patients were randomised to first-line endocrine therapy (letrozole or fulvestrant)&#x000b1;bevacizumab. However, the addition of bevacizumab failed to produce a significant improvement in PFS or OS.<xref rid="R47" ref-type="bibr">47</xref></p></sec><sec id="s3c5"><title>Histone deacetylase inhibitor</title><p>A double-blind phase II trial of exemestane versus exemestane plus the histone deacetylase inhibitor entinostat showed no difference in the predefined end point PFS (4.3 vs 2.3&#x02005;months; p=0.11). However, an exploratory analysis showed improved OS in the experimental arm (28.1 vs 19.8&#x02005;months; p=0.036).<xref rid="R48" ref-type="bibr">48</xref> In a subset of patients, an association of histone deacetylase inhibition with protein lysine acetylation and improved clinical outcome was demonstrated.</p></sec><sec id="s3c6"><title>CDK4/6 inhibitor</title><p>The cyclin-dependent kinases (CDKs) are a large family of serine threonine kinases. Together with their regulatory partners, the cyclins, they play a crucial role in cell cycle control. Preclinical studies have shown synergistic effect of CDK inhibitors and tamoxifen as well as efficacy in a model of acquired tamoxifen resistance.<xref rid="R49" ref-type="bibr">49</xref></p><p>Among several CDK4/6 inhibitors currently in development, palbociclib has been evaluated in a randomised phase II trial of letrozole&#x000b1;palbociclib. Median PFS was 10.2&#x02005;months in the letrozole group compared with 20.2&#x02005;months in the palbociclib+letrozole group (p=0.0004). The study was not powered to detect an OS benefit.<xref rid="R50" ref-type="bibr">50</xref></p></sec><sec id="s3c7"><title>Antibody directed against MUC1</title><p>MUC1 is an aberrantly glycosylated antigen, overexpressed in &#x0223c;90% of breast cancers. Preclinical studies have shown a mechanistic interaction between MUC1 and ER, providing a rationale for evaluation of combination therapy.<xref rid="R51" ref-type="bibr">51</xref> However, a randomised phase II study of letrozole&#x000b1;anti-MUC1 antibody AS1402 failed to demonstrate any benefit of adding AS1402 to letrozole.<xref rid="R52" ref-type="bibr">52</xref></p></sec></sec><sec id="s3d"><title>Studies of combinations of AI/fulvestrant and HER2-targeting agents</title><p>Results from three phase III trials evaluating endocrine therapy in combination with HER2-directed therapy are given in <xref ref-type="table" rid="ESMOOPEN2016000062TB4">table 4</xref>.</p><table-wrap id="ESMOOPEN2016000062TB4" orientation="portrait" position="float"><label>Table&#x000a0;4</label><caption><p>Summary of phase II and III trials of HER2-directed therapy in combination with endocrine therapy in patients with HER2-positive hormone receptor-positive metastatic breast cancer</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Treatment*</th><th align="left" rowspan="1" colspan="1">Number of patients</th><th align="left" rowspan="1" colspan="1">Patient population</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Prior endocrine therapy</th><th align="left" rowspan="1" colspan="1">Prior chemotherapy for ABC</th><th align="left" rowspan="1" colspan="1">RR (%) (95% CI)</th><th align="left" rowspan="1" colspan="1">SD (%) (95% CI)</th><th align="left" rowspan="1" colspan="1">TTP/PFS (median; months) (95% CI)</th><th align="left" rowspan="1" colspan="1">OS (median; months) (95% CI)</th></tr></thead><tbody><tr><td colspan="11" rowspan="1">NSAI; trastuzumab</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Kaufman <italic>et al</italic><xref rid="R54" ref-type="bibr">54</xref></td><td rowspan="1" colspan="1">Anastrozole+trastuzumab</td><td rowspan="1" colspan="1">103</td><td rowspan="2" colspan="1">ER/PGR+ HER2+</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None: 37/29%; adj TAM: 60/66%; first-line endocrine therapy:3/5%; no prior HER-directed therapy</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">20.3</td><td rowspan="1" colspan="1">42.7 (33.0 to 52.9)</td><td rowspan="1" colspan="1">4.8</td><td rowspan="1" colspan="1">28.5</td></tr><tr><td rowspan="1" colspan="1">Anastrozole</td><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">6.8 (p=0.018)</td><td rowspan="1" colspan="1">27.9 (19.5 to 37.5) (CBR)</td><td rowspan="1" colspan="1">2.4 (HR 0.63; p=0.0016)</td><td rowspan="1" colspan="1">23.9 (p=0.325)</td></tr><tr><td colspan="11" rowspan="1">NSAI; lapatinib</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Johnston <italic>et al</italic><xref rid="R55" ref-type="bibr">55</xref></td><td rowspan="1" colspan="1">Letrozole+lapatinib</td><td rowspan="1" colspan="1">642 (111 HER2+)</td><td rowspan="2" colspan="1">ER/PGR+ HER2+ 17/17%</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">None: 51/43%; adj endocrine therapy: 49&#x02013;57%; prior AI &#x02264;1%; prior HER2-directed therapy &#x02264;1%</td><td rowspan="2" colspan="1">None</td><td rowspan="1" colspan="1">28 (HER2+)</td><td rowspan="1" colspan="1">48 (HER2+, CBR)</td><td rowspan="1" colspan="1">8.2 (HER2+)</td><td rowspan="1" colspan="1">32.3 (HER2+)</td></tr><tr><td rowspan="1" colspan="1">Letrozole+placebo</td><td rowspan="1" colspan="1">644 (108 HER2+)</td><td rowspan="1" colspan="1">15 (OR 0.4; 0.2 to 0.9; p=0.021)</td><td rowspan="1" colspan="1">29 (OR 0.2 to 0.8; p=0.003)</td><td rowspan="1" colspan="1">3.0 (HR 0.71; p=0.019)</td><td rowspan="1" colspan="1">33.3 (HR 0.74; p=0.113)</td></tr><tr><td colspan="11" rowspan="1">Fulvestrant; lapatinib</td></tr><tr><td rowspan="2" colspan="1">&#x02003;Burstein <italic>et al</italic><xref rid="R56" ref-type="bibr">56</xref></td><td rowspan="1" colspan="1">Fulvestrant 500&#x02005;mg+lapatinib</td><td rowspan="1" colspan="1">146 (24 HER2+)</td><td rowspan="2" colspan="1">ER/PGR+ HER2+ 16/21%</td><td rowspan="2" colspan="1">III</td><td rowspan="2" colspan="1">Prior TAM: 57/57%; prior AI: 97/97%; setting NR; prior trastuzumab: 2/3%</td><td rowspan="2" colspan="1">&#x02264;1</td><td rowspan="1" colspan="1">38 (14 to 70) (HER2+)</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">4.7 (HER2+)</td><td rowspan="1" colspan="1">30.0 (HER2+)</td></tr><tr><td rowspan="1" colspan="1">Fulvestrant 500&#x02005;mg+placebo</td><td rowspan="1" colspan="1">145 (30 HER2+)</td><td rowspan="1" colspan="1">16 (5 to 45)</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">3.8 (HR 1.04; p=0.37)</td><td rowspan="1" colspan="1">26.4 (HR 0.91; p=0.25)</td></tr></tbody></table><table-wrap-foot><fn><p>For RR, duration of TTP/PFS and OS, the number of decimals used by the authors is reported.</p></fn><fn><p>ER/PGR+, HER2: % positive are given when possible.</p></fn><fn><p>*Doses of anastrozole and letrozole were 1 and 2.5&#x02005;mg, respectively.</p></fn><fn><p>ABC, advanced breast cancer; adj, adjuvant; AI, aromatase inhibitor; CBR, clinical benefit rate; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; NR, not reported; NSAI, non-steroid aromatase inhibitor; PFS, progression-free survival; PRG, progesterone receptor; RR, response rate; SAI, steroid aromatase inhibitor; TAM, tamoxifen; TTP, time to progression; OS, overall survival.</p></fn></table-wrap-foot></table-wrap><p>Studies have shown significant inverse correlation between HER2 and ER expression. Furthermore, preclinical studies suggest an interaction between the two pathways.<xref rid="R53" ref-type="bibr">53</xref> In the first-line setting, trastuzumab+anastrozole compared with anastrozole demonstrated significantly increased median PFS (4.8 vs 2.4&#x02005;months) and increased RR (20.3% vs 6.8%).<xref rid="R54" ref-type="bibr">54</xref></p><p>A phase III trial compared letrozole with letrozole plus the dual HER1/EGFR and HER2 tyrosine kinase inhibitor lapatinib in 1286 patients with HR-positive metastatic breast cancer as first-line therapy. In 219 HER2-positive patients, the addition of lapatinib reduced the risk of disease progression (p=0.019) and increased median PFS (8.2 vs 3.0&#x02005;months).<xref rid="R55" ref-type="bibr">55</xref> Finally, a phase III trial including 295 patients with advanced breast cancer previously treated with an AI compared fulvestrant (250&#x02005;mg) plus lapatinib with fulvestrant plus placebo. In the total patient population, no differences in PFS or OS were found. In 54 HER2-positive patients, however, the addition of lapatinib resulted in a longer median PFS (5.9 vs 3.3&#x02005;months).<xref rid="R56" ref-type="bibr">56</xref></p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Guidelines unanimously recommend endocrine therapy as first choice in patients with HR-positive, HER2-negative disease independent of metastatic site, unless rapid response is needed or in case of doubts regarding the endocrine responsiveness of the tumour.<xref rid="R57" ref-type="bibr">57</xref>
<xref rid="R58" ref-type="bibr">58</xref> This strategy is partly based on consensus between specialists<xref rid="R3" ref-type="bibr">3</xref> and partly on a Cochrane review published in 2003 and updated in 2010.<xref rid="R59" ref-type="bibr">59</xref> No studies published after 2000 have addressed this question.</p><sec id="s4a"><title>Treatment selection</title><sec id="s4a1"><title>First-line therapy</title><p>In general, trials evaluating the different AIs and/or fulvestrant were conducted before the time of systematic HER2 analyses; thus, patients with unknown HR status were included in some of the trials. In addition, studies were conducted at a time when the use of adjuvant AI was uncommon.</p><p>In the first-line setting, NSAIs were more effective than tamoxifen regarding TTP,<xref rid="R7" ref-type="bibr">7</xref>
<xref rid="R8" ref-type="bibr">8</xref>
<xref rid="R10" ref-type="bibr">10</xref>
<xref rid="R13" ref-type="bibr">13</xref> whereas the difference between exemestane and tamoxifen was limited and depended on the statistical test used.<xref rid="R15" ref-type="bibr">15</xref>
<xref rid="R16" ref-type="bibr">16</xref> Except for the P025 trial in which a significant OS benefit was found for letrozole compared with tamoxifen,<xref rid="R60" ref-type="bibr">60</xref> no OS benefit was demonstrated in the trials.</p><p>A recent meta-analysis of six trials including 2560 patients<xref rid="R6" ref-type="bibr">6</xref>
<xref rid="R7" ref-type="bibr">7</xref>
<xref rid="R10" ref-type="bibr">10</xref>
<xref rid="R15" ref-type="bibr">15</xref>
<xref rid="R16" ref-type="bibr">16</xref>
<xref rid="R61" ref-type="bibr">61</xref> comparing an AI with tamoxifen found a significant difference favouring AI regarding RR and CBR. However, a trend towards improved survival was non-significant.<xref rid="R62" ref-type="bibr">62</xref> In contrast, two meta-analyses showed a significant OS benefit of AIs compared with other endocrine therapies.<xref rid="R63" ref-type="bibr">63</xref>
<xref rid="R64" ref-type="bibr">64</xref> Thus, if not used in the adjuvant setting or if discontinued &#x0003e;12&#x02005;months, an NSAI is the preferred option in all guidelines.<xref rid="R57" ref-type="bibr">57</xref>
<xref rid="R58" ref-type="bibr">58</xref> None of the guidelines recommend one NSAI over another. Pharmacokinetic data have shown letrozole to be a more potent suppressor of total body aromatisation and plasma oestrogen levels than anastrozole.<xref rid="R65" ref-type="bibr">65</xref> On the other hand, other data suggested that once a certain threshold of AI was reached, differences in oestrogen suppression were not associated with clinically significant differences in efficacy.<xref rid="R66" ref-type="bibr">66</xref> Increasingly, AIs have become an integral component of standard care of postmenopausal patients in the adjuvant setting.<xref rid="R67" ref-type="bibr">67</xref>
<xref rid="R68" ref-type="bibr">68</xref> Most studies, however, were conducted at a time when adjuvant treatment consisted of tamoxifen. Thus, evidence for first-line recommendations after an adjuvant AI is lacking. Anyhow, European Society for Medical Oncology (ESMO) guidelines suggest that preferably, an NSAI should be used after progression on an SAI and vice versa, whereas National Comprehensive Cancer Network (NCCN) does not distinguish between the AIs.<xref rid="R57" ref-type="bibr">57</xref></p><p>The efficacy of fulvestrant (250&#x02005;mg) did not differ from that of tamoxifen in the first-line setting. Results were independent of prior adjuvant tamoxifen. However, as supported by findings in clinical trials, the recommended dose of fulvestrant is 500&#x02005;mg which is why these results should be interpreted with caution.<xref rid="R69" ref-type="bibr">69&#x02013;72</xref> The 500&#x02005;mg schedule was approved by the Food and Drug Administration (FDA) in 2010. Thus, guidelines underscore that fulvestrant (500&#x02005;mg) has demonstrated superiority compared with anastrozole in the first-line setting. However, no recommendations for fulvestrant exist. More data are awaited. Of note, all guidelines regard tamoxifen as an acceptable first-line therapy.</p></sec><sec id="s4a2"><title>Later lines of therapy</title><sec id="s4a2a"><title>Single-agent or combined endocrine therapy</title><p>In general, the efficacy of the different AIs and fulvestrant was similar in tamoxifen-refractory patients. No study fulfilling the search criteria investigated the impact of treatment sequence. Only one small randomised trial (substudy of TARGET) including 60 patients investigated the impact of the treatment sequence.<xref rid="R73" ref-type="bibr">73</xref> Data suggested that an antioestrogen might be active after an AI. However, the study was not powered to draw firm conclusions. An issue of particular interest is the lack of cross-resistance between SAI and NSAI provided that the NSAI is given upfront. In general, studies reporting on this phenomenon included few patients,<xref rid="R25" ref-type="bibr">25</xref>
<xref rid="R74" ref-type="bibr">74&#x02013;76</xref> but findings across different studies seem to consent that no cross-resistance exists. This is supported by one randomised trial,<xref rid="R34" ref-type="bibr">34</xref> in which exemestane was compared with fulvestrant after failure of an NSAI; no significant differences in efficacy parameters were reported. For the reverse sequence, that is NSAI after failure of an SAI, only one study was identified in which a 55% RR of an NSAI after prior exposure to exemestane was reported.<xref rid="R74" ref-type="bibr">74</xref></p><p>Differences in binding ability, including different binding sites at the aromatase enzyme, kinetics (reversibility) and androgen-agonistic effects, might potentially explain the findings. However, the pharmacologic and molecular mechanisms behind the phenomenon remain unclear.<xref rid="R76" ref-type="bibr">76</xref></p><p>A limited number of small phase II studies and retrospective studies have demonstrated activity of AIs and fulvestrant in the third-line setting.<xref rid="R77" ref-type="bibr">77&#x02013;79</xref> Importantly, the response to previous therapy had little impact on efficacy of the drugs. The results might be due to selection bias and small number of patients. Anyhow, results suggested that the drugs might be active in latter lines of therapy.</p><p>In the SWOG 0226 trial, the combination of anastrozole and fulvestrant (250&#x02005;mg) increased PFS compared with anastrozole alone (15 vs 13.5&#x02005;months). The combination therapy also increased the median OS by &#x0223c;6&#x02005;months despite the fact that 41% of patients crossed over to fulvestrant after progression.<xref rid="R29" ref-type="bibr">29</xref> The FACT trial, which also compared anastrozole&#x000b1;fulvestrant (250&#x02005;mg) as first-line therapy, found no difference in outcome.<xref rid="R28" ref-type="bibr">28</xref> A possible explanation for the discordant results could be that a higher percentage of patients had received prior hormonal therapy in the FACT trial (66&#x02013;70% in FACT vs 40% in SWOG). Thus, a subanalysis of the SWOG trial did not show a significant improvement in PFS in patients who had received adjuvant tamoxifen.<xref rid="R29" ref-type="bibr">29</xref> In addition, the FACT trial was slightly smaller and included patients with local recurrence only, as well as patients who had recurrence while on adjuvant endocrine therapy.</p><p>No guidelines consider combination hormonal therapy to be a standard first-line treatment option. However, in postmenopausal patients who have not received prior hormonal therapy, this option deserves further investigation.</p><p>Generally, guidelines do not definitively recommend specific endocrine treatment cascades, particularly regarding the best treatment option following progression on first-line therapy.<xref rid="R57" ref-type="bibr">57</xref>
<xref rid="R67" ref-type="bibr">67</xref></p></sec></sec><sec id="s4a3"><title>Endocrine therapy combined with other agents</title><p>Studies on endocrine therapy in combination with inhibitors of angiogenesis, COX-2 inhibitors and HER1 inhibitors did not show any benefit of the combinations.</p><p>The histone deacetylase inhibitor entinostat in combination with exemestane is currently evaluated in a phase III study (NCT02115282). Results are expected in July 2017.</p><p>The addition of everolimus to exemestane in the pivotal BOLERO-2 study undoubtedly resulted in a clinically meaningful extension of median PFS by &#x0223c;4.5&#x02005;months after recurrence or progression on an NSAI. An exploratory analysis of first-line therapy showed a nearly tripled PFS. However, data on OS failed to show any significant difference between the two regimens, although an absolute difference of almost 4.5&#x02005;months was observed. In total, 55% of patients experienced grade 3 or 4 side effects in the everolimus arm, and 29% discontinued everolimus because of lack of tolerability. Overall, the number of serious adverse events (SAEs) did not differ from numbers seen in trials including chemotherapy challenging the strategy of applying the most tolerable regimen first.<xref rid="R80" ref-type="bibr">80</xref> Thus, the safety profile may limit practical use and compliance. The randomised phase II study BOLERO-6 comparing everolimus plus exemestane with everolimus alone with capecitabine (NCT01783444) might provide some answers.</p><p>A similar effect of addition of everolimus was found in a randomised phase II study of tamoxifen&#x000b1;everolimus including 111 HER2-negative, HR-positive postmenopausal women with metastatic breast cancer and prior exposure to an AI. The benefit of everolimus was mainly seen in women with acquired resistance to an AI.<xref rid="R81" ref-type="bibr">81</xref></p><p>In contrast, the phase III HORIZON study evaluating the addition of temsirolimus to letrozole failed to show any benefit of the combination.<xref rid="R42" ref-type="bibr">42</xref> The discordant results are not well understood. A possible explanation could be the intermittent doses used in the HORIZON study. Also, a high rate of toxic effects in this study leading to dose reductions/cessation of temsirolimus could affect the outcome. However, the key difference between the two studies was differences in the study populations. In the HORIZON study, 58% were AI na&#x000ef;ve and it was unlikely that acquired resistance was evident in many of the patients. Thus, it has been hypothesised that mTOR inhibitors are more effective in patients previously exposed to endocrine therapy.</p><p>A recent meta-analysis compared everolimus plus exemestane with fulvestrant 250 and 500&#x02005;mg, respectively. The combination of everolimus and exemestane appeared more efficacious than fulvestrant with regard to PFS. A subgroup analysis of patients who had received prior AI showed similar results.<xref rid="R82" ref-type="bibr">82</xref></p><p>Yet, there are no predictive biomarkers to identify patients who benefit from addition of an mTOR inhibitor.</p><p>Recent treatment guidelines from a range of countries recommend addition of everolimus to exemestane for patients recurring/progressing during or following an NSAI even in the presence of visceral disease.<xref rid="R57" ref-type="bibr">57</xref>
<xref rid="R58" ref-type="bibr">58</xref>
<xref rid="R83" ref-type="bibr">83</xref>
<xref rid="R84" ref-type="bibr">84</xref></p><p>Currently, three specific CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib are being tested in clinical trials. More recently, the randomised phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial showed an almost double PFS after addition of palbociclib to letrozole.<xref rid="R50" ref-type="bibr">50</xref> On 3 February 2015, the US FDA granted accelerated approval to palbociclib for use in combination with letrozole.<xref rid="R85" ref-type="bibr">85</xref> To confirm the impressive results, the phase III study (PALAMO-2) is ongoing and results are expected in October 2016 (NCT01740427). Recently, the phase III PALAMO-3 trial including 521 premenopausal and postmenopausal patients with advanced breast cancer who were randomised to fulvestrant+palbociclib or placebo&#x000b1;goserelin demonstrated a significant increase in PFS (9.2 vs 3.8&#x02005;months, HR 0.42, 95% CI 0.32 to 0.56; p&#x0003c;0.001). The number of deaths at the time of the analysis was insufficient to assess OS.<xref rid="R86" ref-type="bibr">86</xref></p><p>Several phase III studies are in progress with all three CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer. The observed toxicities so far are predominantly hematological, characterised by limited neutropenia. Other common adverse events were infections, fatigue and gastrointestinal toxicity. The toxicities seem manageable. Currently, data are too limited to differentiate between the compounds. No predictive biomarkers to identify patients who benefit from addition of a CDK4/6 inhibitor are available.<xref rid="R87" ref-type="bibr">87</xref></p></sec><sec id="s4a4"><title>Studies of combinations of AI/fulvestrant and HER2-targeting agents</title><p>Approximately half of the patients with HER2-positive breast cancer are also HR positive. Concomitant treatment with anastrozole and therapy directed against HER2 provided a significantly better outcome. The Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer (eLEcTRA) study (92 patients) evaluating letrozole&#x000b1;trastuzumab confirmed these finding.<xref rid="R88" ref-type="bibr">88</xref> Nonetheless, combination chemotherapy with HER2-directed therapy as first-line treatment is generally preferred.<xref rid="R57" ref-type="bibr">57</xref>
<xref rid="R89" ref-type="bibr">89</xref></p></sec></sec><sec id="s4b"><title>Future perspectives</title><p>A major limitation of endocrine therapy is intrinsic and acquired resistance. Although expression of ER is strongly predictive of response to endocrine therapies, approximately one-third of ER-positive cancers do not respond or relapse after an initial response.<xref rid="R90" ref-type="bibr">90</xref> In the past decade, there have been major efforts to understand the molecular mechanism responsible for development of endocrine resistance.<xref rid="R91" ref-type="bibr">91</xref>
<xref rid="R92" ref-type="bibr">92</xref> Drug resistance to single-agent therapy might be driven by pathway reactivation, suggesting that one limitation lies in the inability to fully block the pathway. mTOR and CDK4/6 inhibition might represent ways to overcome this. Furthermore, future strategies currently under evaluation include combining endocrine therapy with inhibitors of growth factor receptors or downstream signalling pathways. For a comprehensive review, see Palmieri <italic>et al</italic>.<xref rid="R93" ref-type="bibr">93</xref> On the other hand, ER-positive breast cancer is biologically heterogeneous, and many patients have long-lasting benefit of endocrine monotherapy.<xref rid="R94" ref-type="bibr">94</xref> Yet, prognostic biomarkers to identify patients who will do well with endocrine therapy alone as well as biomarkers to predict benefit from combination therapy are lacking.</p></sec></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>Conventional treatment with an AI or fulvestrant may be an adequate treatment option for the majority of patients. mTOR and CDK4/6 inhibition might represent substantial advances for patients with HR-positive, HER2-negative advanced breast cancer. However, there is an urgent need for prospective biomarker-driven trials to identify patients for whom the treatments are cost-effective.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name>, <name><surname>Bray</surname><given-names>F</given-names></name>, <name><surname>Siegel</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Global cancer statistics, 2012</article-title>. <source>CA Cancer J Clin</source>
<year>2015</year>;<volume>65</volume>:<fpage>87</fpage>&#x02013;<lpage>108</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3322/caac.21262">doi:10.3322/caac.21262</ext-link><pub-id pub-id-type="pmid">25651787</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>IE</given-names></name>, <name><surname>Dowsett</surname><given-names>M</given-names></name></person-group>
<article-title>Aromatase inhibitors in breast cancer</article-title>. <source>N Engl J Med</source>
<year>2003</year>;<volume>348</volume>:<fpage>2431</fpage>&#x02013;<lpage>42</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMra023246">doi:10.1056/NEJMra023246</ext-link><pub-id pub-id-type="pmid">12802030</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>F</given-names></name>, <name><surname>Bischoff</surname><given-names>J</given-names></name>, <name><surname>Brain</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women</article-title>. <source>Cancer Treat Rev</source>
<year>2013</year>;<volume>39</volume>:<fpage>457</fpage>&#x02013;<lpage>65</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ctrv.2012.06.011">doi:10.1016/j.ctrv.2012.06.011</ext-link><pub-id pub-id-type="pmid">22840697</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>RW</given-names></name></person-group>
<article-title>The history and mechanism of action of fulvestrant</article-title>. <source>Clin Breast Cancer</source>
<year>2005</year>;<volume>6</volume>(Suppl <issue>1</issue>):<fpage>S5</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3816/CBC.2005.s.008">doi:10.3816/CBC.2005.s.008</ext-link><pub-id pub-id-type="pmid">15865849</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciruelos</surname><given-names>E</given-names></name>, <name><surname>Pascual</surname><given-names>T</given-names></name>, <name><surname>Arroyo Vozmediano</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer</article-title>. <source>Breast</source>
<year>2014</year>;<volume>23</volume>:<fpage>201</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.breast.2014.01.016">doi:10.1016/j.breast.2014.01.016</ext-link><pub-id pub-id-type="pmid">24589524</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonneterre</surname><given-names>J</given-names></name>, <name><surname>Thurlimann</surname><given-names>B</given-names></name>, <name><surname>Robertson</surname><given-names>JF</given-names></name><etal/></person-group>
<article-title>Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study</article-title>. <source>J Clin Oncol</source>
<year>2000</year>;<volume>18</volume>:<fpage>3748</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">11078487</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabholtz</surname><given-names>JM</given-names></name>, <name><surname>Buzdar</surname><given-names>A</given-names></name>, <name><surname>Pollak</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group</article-title>. <source>J Clin Oncol</source>
<year>2000</year>;<volume>18</volume>:<fpage>3758</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">11078488</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonneterre</surname><given-names>J</given-names></name>, <name><surname>Buzdar</surname><given-names>A</given-names></name>, <name><surname>Nabholtz</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma</article-title>. <source>Cancer</source>
<year>2001</year>;<volume>92</volume>:<fpage>2247</fpage>&#x02013;<lpage>58</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/1097-0142(20011101)92:9&#x0003c;2247::AID-CNCR1570&#x0003e;3.0.CO;2-Y">doi:10.1002/1097-0142(20011101)92:9&#x0003c;2247::AID-CNCR1570&#x0003e;3.0.CO;2-Y</ext-link><pub-id pub-id-type="pmid">11745278</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabholtz</surname><given-names>JM</given-names></name>, <name><surname>Bonneterre</surname><given-names>J</given-names></name>, <name><surname>Buzdar</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results</article-title>. <source>Eur J Cancer</source>
<year>2003</year>;<volume>39</volume>:<fpage>1684</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0959-8049(03)00326-5">doi:10.1016/S0959-8049(03)00326-5</ext-link><pub-id pub-id-type="pmid">12888362</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milla-Santos</surname><given-names>A</given-names></name>, <name><surname>Milla</surname><given-names>L</given-names></name>, <name><surname>Portella</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study</article-title>. <source>Am J Clin Oncol</source>
<year>2003</year>;<volume>26</volume>:<fpage>317</fpage>&#x02013;<lpage>22</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.COC.0000047126.10522.F9">doi:10.1097/01.COC.0000047126.10522.F9</ext-link><pub-id pub-id-type="pmid">12796608</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>H</given-names></name>, <name><surname>Gershanovich</surname><given-names>M</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group</article-title>. <source>J Clin Oncol</source>
<year>2001</year>;<volume>19</volume>:<fpage>2596</fpage>&#x02013;<lpage>606</lpage>.<pub-id pub-id-type="pmid">11352951</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>H</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Gershanovich</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability</article-title>. <source>Oncologist</source>
<year>2004</year>;<volume>9</volume>:<fpage>489</fpage>&#x02013;<lpage>96</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1634/theoncologist.9-5-489">doi:10.1634/theoncologist.9-5-489</ext-link><pub-id pub-id-type="pmid">15477633</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>H</given-names></name>, <name><surname>Gershanovich</surname><given-names>M</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group</article-title>. <source>J Clin Oncol</source>
<year>2003</year>;<volume>21</volume>:<fpage>2101</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2003.04.194">doi:10.1200/JCO.2003.04.194</ext-link><pub-id pub-id-type="pmid">12775735</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>HT</given-names></name>, <name><surname>Chaudri-Ross</surname><given-names>HA</given-names></name></person-group>
<article-title>Comment on &#x0201c;Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results&#x0201d; by J.-M. Nabholtz <italic>et al</italic></article-title>. <source>Eur J Cancer</source>
<year>2004</year>;<volume>40</volume>:<fpage>1095</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15093587</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paridaens</surname><given-names>R</given-names></name>, <name><surname>Dirix</surname><given-names>L</given-names></name>, <name><surname>Lohrisch</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer</article-title>. <source>Ann Oncol</source>
<year>2003</year>;<volume>14</volume>:
<fpage>1391</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdg362">doi:10.1093/annonc/mdg362</ext-link><pub-id pub-id-type="pmid">12954578</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paridaens</surname><given-names>RJ</given-names></name>, <name><surname>Dirix</surname><given-names>LY</given-names></name>, <name><surname>Beex</surname><given-names>LV</given-names></name><etal/></person-group>
<article-title>Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group</article-title>. <source>J Clin Oncol</source>
<year>2008</year>;<volume>26</volume>:<fpage>4883</fpage>&#x02013;<lpage>90</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2007.14.4659">doi:10.1200/JCO.2007.14.4659</ext-link><pub-id pub-id-type="pmid">18794551</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>A</given-names></name>, <name><surname>Robertson</surname><given-names>JF</given-names></name>, <name><surname>Abram</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial</article-title>. <source>J Clin Oncol</source>
<year>2004</year>;<volume>22</volume>:<fpage>1605</fpage>&#x02013;<lpage>13</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2004.02.112">doi:10.1200/JCO.2004.02.112</ext-link><pub-id pub-id-type="pmid">15117982</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzdar</surname><given-names>AU</given-names></name>, <name><surname>Jones</surname><given-names>SE</given-names></name>, <name><surname>Vogel</surname><given-names>CL</given-names></name><etal/></person-group>
<article-title>A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group</article-title>. <source>Cancer</source>
<year>1997</year>;<volume>79</volume>:<fpage>730</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9024711</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonat</surname><given-names>W</given-names></name>, <name><surname>Howell</surname><given-names>A</given-names></name>, <name><surname>Blomqvist</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer</article-title>. <source>Eur J Cancer</source>
<year>1996</year>;<volume>32A</volume>:<fpage>404</fpage>&#x02013;<lpage>12</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0959-8049(95)00014-3">doi:10.1016/0959-8049(95)00014-3</ext-link><pub-id pub-id-type="pmid">8814682</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzdar</surname><given-names>AU</given-names></name>, <name><surname>Jonat</surname><given-names>W</given-names></name>, <name><surname>Howell</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group</article-title>. <source>Cancer</source>
<year>1998</year>;<volume>83</volume>:<fpage>1142</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">9740079</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzdar</surname><given-names>A</given-names></name>, <name><surname>Douma</surname><given-names>J</given-names></name>, <name><surname>Davidson</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate</article-title>. <source>J Clin Oncol</source>
<year>2001</year>;<volume>19</volume>:<fpage>3357</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">11454883</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dombernowsky</surname><given-names>P</given-names></name>, <name><surname>Smith</surname><given-names>I</given-names></name>, <name><surname>Falkson</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate</article-title>. <source>J Clin Oncol</source>
<year>1998</year>;<volume>16</volume>:<fpage>453</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">9469328</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>M</given-names></name>, <name><surname>Bajetta</surname><given-names>E</given-names></name>, <name><surname>Dirix</surname><given-names>LY</given-names></name><etal/></person-group>
<article-title>Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study</article-title>. <source>Clin Breast Cancer</source>
<year>2000</year>;<volume>1</volume>(Suppl <issue>1</issue>):<fpage>S15</fpage>&#x02013;<lpage>18</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3816/CBC.2000.s.003">doi:10.3816/CBC.2000.s.003</ext-link><pub-id pub-id-type="pmid">11970744</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>H</given-names></name>, <name><surname>Masuda</surname><given-names>N</given-names></name>, <name><surname>Ohno</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer</article-title>. <source>Breast Cancer Res Treat</source>
<year>2013</year>;<volume>139</volume>:<fpage>441</fpage>&#x02013;<lpage>51</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-013-2573-3">doi:10.1007/s10549-013-2573-3</ext-link><pub-id pub-id-type="pmid">23715630</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llombart-Cussac</surname><given-names>A</given-names></name>, <name><surname>Ruiz</surname><given-names>A</given-names></name>, <name><surname>Anton</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001&#x02013;03 phase 2 randomized trial</article-title>. <source>Cancer</source>
<year>2012</year>;<volume>118</volume>:<fpage>241</fpage>&#x02013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.26299">doi:10.1002/cncr.26299</ext-link><pub-id pub-id-type="pmid">21717449</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>JF</given-names></name>, <name><surname>Lindemann</surname><given-names>JP</given-names></name>, <name><surname>Llombart-Cussac</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized &#x02018;FIRST&#x02019; study</article-title>. <source>Breast Cancer Res Treat</source>
<year>2012</year>;<volume>136</volume>:<fpage>503</fpage>&#x02013;<lpage>11</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-012-2192-4">doi:10.1007/s10549-012-2192-4</ext-link><pub-id pub-id-type="pmid">23065000</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>JF</given-names></name>, <name><surname>Llombart-Cussac</surname><given-names>A</given-names></name>, <name><surname>Rolski</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</article-title>. <source>J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>4530</fpage>&#x02013;<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2008.21.1136">doi:10.1200/JCO.2008.21.1136</ext-link><pub-id pub-id-type="pmid">19704066</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergh</surname><given-names>J</given-names></name>, <name><surname>Jonsson</surname><given-names>PE</given-names></name>, <name><surname>Lidbrink</surname><given-names>EK</given-names></name><etal/></person-group>
<article-title>FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer</article-title>. <source>J Clin Oncol</source>
<year>2012</year>;<volume>30</volume>:<fpage>1919</fpage>&#x02013;<lpage>25</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2011.38.1095">doi:10.1200/JCO.2011.38.1095</ext-link><pub-id pub-id-type="pmid">22370325</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RS</given-names></name>, <name><surname>Barlow</surname><given-names>WE</given-names></name>, <name><surname>Albain</surname><given-names>KS</given-names></name><etal/></person-group>
<article-title>Combination anastrozole and fulvestrant in metastatic breast cancer</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>367</volume>:<fpage>435</fpage>&#x02013;<lpage>44</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1201622">doi:10.1056/NEJMoa1201622</ext-link><pub-id pub-id-type="pmid">22853014</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>C</given-names></name>, <name><surname>Vtoraya</surname><given-names>O</given-names></name>, <name><surname>Pluzanska</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole</article-title>. <source>Eur J Cancer</source>
<year>2003</year>;<volume>39</volume>:<fpage>2318</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">14556923</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>A</given-names></name>, <name><surname>Robertson</surname><given-names>JF</given-names></name>, <name><surname>Quaresma Albano</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment</article-title>. <source>J Clin Oncol</source>
<year>2002</year>;<volume>20</volume>:<fpage>3396</fpage>&#x02013;<lpage>403</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2002.10.057">doi:10.1200/JCO.2002.10.057</ext-link><pub-id pub-id-type="pmid">12177099</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name>, <name><surname>Jiang</surname><given-names>Z</given-names></name>, <name><surname>Shao</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2011</year>;<volume>67</volume>:<fpage>223</fpage>&#x02013;<lpage>30</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00280-010-1483-x">doi:10.1007/s00280-010-1483-x</ext-link><pub-id pub-id-type="pmid">20938664</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>JF</given-names></name>, <name><surname>Osborne</surname><given-names>CK</given-names></name>, <name><surname>Howell</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials</article-title>. <source>Cancer</source>
<year>2003</year>;<volume>98</volume>:<fpage>229</fpage>&#x02013;<lpage>38</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.11468">doi:10.1002/cncr.11468</ext-link><pub-id pub-id-type="pmid">12872340</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>S</given-names></name>, <name><surname>Gradishar</surname><given-names>W</given-names></name>, <name><surname>Mauriac</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT</article-title>. <source>J Clin Oncol</source>
<year>2008</year>;<volume>26</volume>:<fpage>1664</fpage>&#x02013;<lpage>70</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2007.13.5822">doi:10.1200/JCO.2007.13.5822</ext-link><pub-id pub-id-type="pmid">18316794</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SR</given-names></name>, <name><surname>Kilburn</surname><given-names>LS</given-names></name>, <name><surname>Ellis</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>;<volume>14</volume>:<fpage>989</fpage>&#x02013;<lpage>98</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(13)70322-X">doi:10.1016/S1470-2045(13)70322-X</ext-link><pub-id pub-id-type="pmid">23902874</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falandry</surname><given-names>C</given-names></name>, <name><surname>Debled</surname><given-names>M</given-names></name>, <name><surname>Bachelot</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study</article-title>. <source>Breast Cancer Res Treat</source>
<year>2009</year>;<volume>116</volume>:<fpage>501</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-008-0229-5">doi:10.1007/s10549-008-0229-5</ext-link><pub-id pub-id-type="pmid">19020973</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirix</surname><given-names>LY</given-names></name>, <name><surname>Ignacio</surname><given-names>J</given-names></name>, <name><surname>Nag</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib</article-title>. <source>J Clin Oncol</source>
<year>2008</year>;<volume>26</volume>:<fpage>1253</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2007.13.3744">doi:10.1200/JCO.2007.13.3744</ext-link><pub-id pub-id-type="pmid">18323548</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciruelos Gil</surname><given-names>EM</given-names></name></person-group>
<article-title>Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer</article-title>. <source>Cancer Treat Rev</source>
<year>2014</year>;<volume>40</volume>:<fpage>862</fpage>&#x02013;<lpage>71</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ctrv.2014.03.004">doi:10.1016/j.ctrv.2014.03.004</ext-link><pub-id pub-id-type="pmid">24774538</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J</given-names></name>, <name><surname>Campone</surname><given-names>M</given-names></name>, <name><surname>Piccart</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>366</volume>:<fpage>520</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1109653">doi:10.1056/NEJMoa1109653</ext-link><pub-id pub-id-type="pmid">22149876</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Piccart</surname><given-names>M</given-names></name>, <name><surname>Hortobagyi</surname><given-names>G</given-names></name>, <name><surname>Campone</surname><given-names>M</given-names></name><etal/></person-group>
<comment>Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Presented at EBCC-9; 19&#x02013;21 March 2014</comment>; <publisher-loc>Glasgow, UK</publisher-loc>, <year>2014</year>.</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>JT</given-names></name>, <name><surname>Hortobagyi</surname><given-names>GN</given-names></name>, <name><surname>Campone</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Everolimus plus exemestane as first-line therapy in HR(+), HER2(&#x02212;) advanced breast cancer in BOLERO-2</article-title>. <source>Breast Cancer Res Treat</source>
<year>2014</year>;<volume>143</volume>:<fpage>459</fpage>&#x02013;<lpage>67</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-013-2814-5">doi:10.1007/s10549-013-2814-5</ext-link><pub-id pub-id-type="pmid">24362951</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name>, <name><surname>Lazar</surname><given-names>AA</given-names></name>, <name><surname>Bondarenko</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer</article-title>. <source>J Clin Oncol</source>
<year>2013</year>;<volume>31</volume>:<fpage>195</fpage>&#x02013;<lpage>202</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2011.38.3331">doi:10.1200/JCO.2011.38.3331</ext-link><pub-id pub-id-type="pmid">23233719</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>RI</given-names></name>, <name><surname>McClelland</surname><given-names>RA</given-names></name>, <name><surname>Gee</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy</article-title>. <source>Breast Cancer Res Treat</source>
<year>1994</year>;<volume>29</volume>:<fpage>117</fpage>&#x02013;<lpage>25</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF00666187">doi:10.1007/BF00666187</ext-link><pub-id pub-id-type="pmid">7912565</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klijn</surname><given-names>JG</given-names></name>, <name><surname>Berns</surname><given-names>PM</given-names></name>, <name><surname>Schmitz</surname><given-names>PI</given-names></name><etal/></person-group>
<article-title>The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients</article-title>. <source>Endocr Rev</source>
<year>1992</year>;<volume>13</volume>:<fpage>3</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">1313356</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>RW</given-names></name>, <name><surname>O'Neill</surname><given-names>A</given-names></name>, <name><surname>Vidaurre</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer</article-title>. <source>Breast Cancer Res Treat</source>
<year>2012</year>;<volume>133</volume>:<fpage>1049</fpage>&#x02013;<lpage>56</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-012-1997-5">doi:10.1007/s10549-012-1997-5</ext-link><pub-id pub-id-type="pmid">22418699</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutteridge</surname><given-names>E</given-names></name>, <name><surname>Agrawal</surname><given-names>A</given-names></name>, <name><surname>Nicholson</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study</article-title>. <source>Int J Cancer</source>
<year>2010</year>;<volume>126</volume>:<fpage>1806</fpage>&#x02013;<lpage>16</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.24884">doi:10.1002/ijc.24884</ext-link><pub-id pub-id-type="pmid">19739079</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name>, <name><surname>Loibl</surname><given-names>S</given-names></name>, <name><surname>von Minckwitz</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study</article-title>. <source>J Clin Oncol</source>
<year>2015</year>;<volume>33</volume>:<fpage>1045</fpage>&#x02013;<lpage>52</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2014.57.2388">doi:10.1200/JCO.2014.57.2388</ext-link><pub-id pub-id-type="pmid">25691671</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yardley</surname><given-names>DA</given-names></name>, <name><surname>Ismail-Khan</surname><given-names>RR</given-names></name>, <name><surname>Melichar</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor</article-title>. <source>J Clin Oncol</source>
<year>2013</year>;<volume>31</volume>:<fpage>2128</fpage>&#x02013;<lpage>35</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2012.43.7251">doi:10.1200/JCO.2012.43.7251</ext-link><pub-id pub-id-type="pmid">23650416</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name>, <name><surname>Dering</surname><given-names>J</given-names></name>, <name><surname>Conklin</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro</article-title>. <source>Breast Cancer Res</source>
<year>2009</year>;<volume>11</volume>:<fpage>R77</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/bcr2419">doi:10.1186/bcr2419</ext-link><pub-id pub-id-type="pmid">19874578</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name>, <name><surname>Crown</surname><given-names>JP</given-names></name>, <name><surname>Lang</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study</article-title>. <source>Lancet Oncol</source>
<year>2015</year>;<volume>16</volume>:<fpage>25</fpage>&#x02013;<lpage>35</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(14)71159-3">doi:10.1016/S1470-2045(14)71159-3</ext-link><pub-id pub-id-type="pmid">25524798</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>H</given-names></name>, <name><surname>Kufe</surname><given-names>D</given-names></name></person-group>
<article-title>MUC1 oncoprotein stabilizes and activates estrogen receptor alpha</article-title>. <source>Mol Cell</source>
<year>2006</year>;<volume>21</volume>:<fpage>295</fpage>&#x02013;<lpage>305</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2005.11.030">doi:10.1016/j.molcel.2005.11.030</ext-link><pub-id pub-id-type="pmid">16427018</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>NK</given-names></name>, <name><surname>Yariz</surname><given-names>KO</given-names></name>, <name><surname>Bondarenko</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer</article-title>. <source>Clin Cancer Res</source>
<year>2011</year>;<volume>17</volume>:<fpage>6822</fpage>&#x02013;<lpage>30</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-11-1151">doi:10.1158/1078-0432.CCR-11-1151</ext-link><pub-id pub-id-type="pmid">21878535</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shou</surname><given-names>J</given-names></name>, <name><surname>Massarweh</surname><given-names>S</given-names></name>, <name><surname>Osborne</surname><given-names>CK</given-names></name><etal/></person-group>
<article-title>Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer</article-title>. <source>J Natl Cancer Inst</source>
<year>2004</year>;<volume>96</volume>:<fpage>926</fpage>&#x02013;<lpage>35</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djh166">doi:10.1093/jnci/djh166</ext-link><pub-id pub-id-type="pmid">15199112</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>B</given-names></name>, <name><surname>Mackey</surname><given-names>JR</given-names></name>, <name><surname>Clemens</surname><given-names>MR</given-names></name><etal/></person-group>
<article-title>Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study</article-title>. <source>J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>5529</fpage>&#x02013;<lpage>37</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2008.20.6847">doi:10.1200/JCO.2008.20.6847</ext-link><pub-id pub-id-type="pmid">19786670</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>S</given-names></name>, <name><surname>Pippen</surname><given-names>J</given-names><suffix>Jr</suffix></name>, <name><surname>Pivot</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer</article-title>. <source>J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>5538</fpage>&#x02013;<lpage>46</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2009.23.3734">doi:10.1200/JCO.2009.23.3734</ext-link><pub-id pub-id-type="pmid">19786658</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>HJ</given-names></name>, <name><surname>Cirrincione</surname><given-names>CT</given-names></name>, <name><surname>Barry</surname><given-names>WT</given-names></name><etal/></person-group>
<article-title>endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)</article-title>. <source>J Clin Oncol</source>
<year>2014</year>;<volume>32</volume>:<fpage>3959</fpage>&#x02013;<lpage>66</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2014.56.7941">doi:10.1200/JCO.2014.56.7941</ext-link><pub-id pub-id-type="pmid">25348000</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>F</given-names></name>, <name><surname>Costa</surname><given-names>A</given-names></name>, <name><surname>Norton</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)</article-title>. <source>Breast</source>
<year>2014</year>;<volume>23</volume>:<fpage>489</fpage>&#x02013;<lpage>502</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.breast.2014.08.009">doi:10.1016/j.breast.2014.08.009</ext-link><pub-id pub-id-type="pmid">25244983</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradishar</surname><given-names>WJ</given-names></name></person-group>
<article-title>Treatment of metastatic breast cancer</article-title>. <source>J Natl Compr Canc Netw</source>
<year>2014</year>;<volume>12</volume>(<issue>5</issue> Suppl):<fpage>759</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">24853211</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>N</given-names></name>, <name><surname>Hornbuckle</surname><given-names>J</given-names></name>, <name><surname>Ghersi</surname><given-names>D</given-names></name></person-group>
<article-title>Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2003</year>;<issue>(2)</issue>:<fpage>CD002747</fpage>.<pub-id pub-id-type="pmid">12804433</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>HT</given-names></name></person-group>
<article-title>Letrozole in advanced breast cancer: the PO25 trial</article-title>. <source>Breast Cancer Res Treat</source>
<year>2007</year>;<volume>105</volume>(Suppl <issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>29</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-007-9570-3">doi:10.1007/s10549-007-9570-3</ext-link><pub-id pub-id-type="pmid">17333340</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>H</given-names></name>, <name><surname>Chaudri-Ross</surname><given-names>HA</given-names></name></person-group>
<article-title>Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer</article-title>. <source>Oncologist</source>
<year>2004</year>;<volume>9</volume>:<fpage>497</fpage>&#x02013;<lpage>506</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1634/theoncologist.9-5-497">doi:10.1634/theoncologist.9-5-497</ext-link><pub-id pub-id-type="pmid">15477634</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HB</given-names></name>, <name><surname>Liu</surname><given-names>YJ</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name></person-group>
<article-title>Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis</article-title>. <source>Clin Breast Cancer</source>
<year>2011</year>;<volume>11</volume>:<fpage>246</fpage>&#x02013;<lpage>51</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clbc.2011.06.003">doi:10.1016/j.clbc.2011.06.003</ext-link><pub-id pub-id-type="pmid">21737354</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>L</given-names></name>, <name><surname>Lawrence</surname><given-names>D</given-names></name>, <name><surname>Dawson</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2009</year>;<issue>(4)</issue>:<fpage>CD003370</fpage>.<pub-id pub-id-type="pmid">19821307</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauri</surname><given-names>D</given-names></name>, <name><surname>Pavlidis</surname><given-names>N</given-names></name>, <name><surname>Polyzos</surname><given-names>NP</given-names></name><etal/></person-group>
<article-title>Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis</article-title>. <source>J Natl Cancer Inst</source>
<year>2006</year>;<volume>98</volume>:<fpage>1285</fpage>&#x02013;<lpage>91</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djj357">doi:10.1093/jnci/djj357</ext-link><pub-id pub-id-type="pmid">16985247</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>J</given-names></name>, <name><surname>Haynes</surname><given-names>B</given-names></name>, <name><surname>Anker</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study</article-title>. <source>J Clin Oncol</source>
<year>2002</year>;<volume>20</volume>:<fpage>751</fpage>&#x02013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.20.3.751">doi:10.1200/JCO.20.3.751</ext-link><pub-id pub-id-type="pmid">11821457</pub-id></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sainsbury</surname><given-names>R</given-names></name></person-group>
<article-title>Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?</article-title>
<source>Br J Cancer</source>
<year>2004</year>;<volume>90</volume>:<fpage>1733</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.bjc.6601731">doi:10.1038/sj.bjc.6601731</ext-link><pub-id pub-id-type="pmid">15150604</pub-id></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradishar</surname><given-names>WJ</given-names></name>, <name><surname>Anderson</surname><given-names>BO</given-names></name>, <name><surname>Blair</surname><given-names>SL</given-names></name><etal/></person-group>
<article-title>Breast cancer version 3.2014</article-title>. <source>J Natl Compr Canc Netw</source>
<year>2014</year>;<volume>12</volume>:<fpage>542</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">24717572</pub-id></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senkus</surname><given-names>E</given-names></name>, <name><surname>Kyriakides</surname><given-names>S</given-names></name>, <name><surname>Penault-Llorca</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source>
<year>2013</year>;<volume>24</volume>(Suppl <issue>6</issue>):<fpage>vi7</fpage>&#x02013;<lpage>23</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdt284">doi:10.1093/annonc/mdt284</ext-link><pub-id pub-id-type="pmid">23970019</pub-id></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname><given-names>S</given-names></name>, <name><surname>Rai</surname><given-names>Y</given-names></name>, <name><surname>Iwata</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)</article-title>. <source>Ann Oncol</source>
<year>2010</year>;<volume>21</volume>:<fpage>2342</fpage>&#x02013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdq249">doi:10.1093/annonc/mdq249</ext-link><pub-id pub-id-type="pmid">20494961</pub-id></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Leo</surname><given-names>A</given-names></name>, <name><surname>Jerusalem</surname><given-names>G</given-names></name>, <name><surname>Petruzelka</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer</article-title>. <source>J Clin Oncol</source>
<year>2010</year>;<volume>28</volume>:<fpage>4594</fpage>&#x02013;<lpage>600</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2010.28.8415">doi:10.1200/JCO.2010.28.8415</ext-link><pub-id pub-id-type="pmid">20855825</pub-id></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Leo</surname><given-names>A</given-names></name>, <name><surname>Jerusalem</surname><given-names>G</given-names></name>, <name><surname>Petruzelka</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial</article-title>. <source>J Natl Cancer Inst</source>
<year>2014</year>;<volume>106</volume>:<fpage>djt337</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djt337">doi:10.1093/jnci/djt337</ext-link><pub-id pub-id-type="pmid">24317176</pub-id></mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>KI</given-names></name>, <name><surname>Rolski</surname><given-names>J</given-names></name>, <name><surname>Papai</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)</article-title>. <source>Breast Cancer Res Treat</source>
<year>2010</year>;<volume>123</volume>:<fpage>453</fpage>&#x02013;<lpage>61</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-010-1022-9">doi:10.1007/s10549-010-1022-9</ext-link><pub-id pub-id-type="pmid">20632084</pub-id></mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurlimann</surname><given-names>B</given-names></name>, <name><surname>Hess</surname><given-names>D</given-names></name>, <name><surname>Koberle</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Anastrozole (&#x02018;Arimidex&#x02019;) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or &#x02018;Arimidex&#x02019; Randomized Group Efficacy and Tolerability) trial</article-title>. <source>Breast Cancer Res Treat</source>
<year>2004</year>;<volume>85</volume>:<fpage>247</fpage>&#x02013;<lpage>54</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1023/B:BREA.0000025420.78346.f9">doi:10.1023/B:BREA.0000025420.78346.f9</ext-link><pub-id pub-id-type="pmid">15111763</pub-id></mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertelli</surname><given-names>G</given-names></name>, <name><surname>Garrone</surname><given-names>O</given-names></name>, <name><surname>Merlano</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer</article-title>. <source>Oncology</source>
<year>2005</year>;<volume>69</volume>:<fpage>471</fpage>&#x02013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000090985">doi:10.1159/000090985</ext-link><pub-id pub-id-type="pmid">16410685</pub-id></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper-Wynne</surname><given-names>C</given-names></name>, <name><surname>Coombes</surname><given-names>RC</given-names></name></person-group>
<article-title>Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy</article-title>. <source>Eur J Cancer</source>
<year>1999</year>;<volume>35</volume>:<fpage>744</fpage>&#x02013;<lpage>6</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0959-8049(99)00015-5">doi:10.1016/S0959-8049(99)00015-5</ext-link><pub-id pub-id-type="pmid">10505035</pub-id></mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonning</surname><given-names>PE</given-names></name></person-group>
<article-title>Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?</article-title>
<source>Eur J Cancer</source>
<year>2009</year>;<volume>45</volume>:<fpage>527</fpage>&#x02013;<lpage>35</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejca.2008.10.019">doi:10.1016/j.ejca.2008.10.019</ext-link><pub-id pub-id-type="pmid">19062270</pub-id></mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlini</surname><given-names>P</given-names></name>, <name><surname>Michelotti</surname><given-names>A</given-names></name>, <name><surname>Ferretti</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients</article-title>. <source>Cancer Invest</source>
<year>2007</year>;<volume>25</volume>:<fpage>102</fpage>&#x02013;<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/07357900701224789">doi:10.1080/07357900701224789</ext-link><pub-id pub-id-type="pmid">17453821</pub-id></mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>YS</given-names></name>, <name><surname>Beresford</surname><given-names>MJ</given-names></name>, <name><surname>Ravichandran</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer</article-title>. <source>Breast</source>
<year>2007</year>;<volume>16</volume>:<fpage>436</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.breast.2007.02.002">doi:10.1016/j.breast.2007.02.002</ext-link><pub-id pub-id-type="pmid">17418575</pub-id></mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>S</given-names></name>, <name><surname>Perez</surname><given-names>A</given-names></name>, <name><surname>Tan-Chiu</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience</article-title>. <source>Breast Cancer Res Treat</source>
<year>2004</year>;<volume>88</volume>:<fpage>103</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-004-0748-7">doi:10.1007/s10549-004-0748-7</ext-link><pub-id pub-id-type="pmid">15564793</pub-id></mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brufsky</surname><given-names>AM</given-names></name>, <name><surname>Hurvitz</surname><given-names>S</given-names></name>, <name><surname>Perez</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer</article-title>. <source>J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>:<fpage>4286</fpage>&#x02013;<lpage>93</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2010.34.1255">doi:10.1200/JCO.2010.34.1255</ext-link><pub-id pub-id-type="pmid">21990397</pub-id></mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachelot</surname><given-names>T</given-names></name>, <name><surname>Bourgier</surname><given-names>C</given-names></name>, <name><surname>Cropet</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study</article-title>. <source>J Clin Oncol</source>
<year>2012</year>;<volume>30</volume>:<fpage>2718</fpage>&#x02013;<lpage>24</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2011.39.0708">doi:10.1200/JCO.2011.39.0708</ext-link><pub-id pub-id-type="pmid">22565002</pub-id></mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachelot</surname><given-names>T</given-names></name>, <name><surname>McCool</surname><given-names>R</given-names></name>, <name><surname>Duffy</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis</article-title>. <source>Breast Cancer Res Treat</source>
<year>2014</year>;<volume>143</volume>:<fpage>125</fpage>&#x02013;<lpage>33</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-013-2778-5">doi:10.1007/s10549-013-2778-5</ext-link><pub-id pub-id-type="pmid">24272078</pub-id></mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbeck</surname><given-names>N</given-names></name>, <name><surname>Marschner</surname><given-names>N</given-names></name>, <name><surname>Untch</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective</article-title>. <source>Breast Care (Basel)</source>
<year>2014</year>;<volume>9</volume>:<fpage>52</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000358689">doi:10.1159/000358689</ext-link><pub-id pub-id-type="pmid">24803888</pub-id></mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>KI</given-names></name>, <name><surname>Gelmon</surname><given-names>KA</given-names></name>, <name><surname>Rayson</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement</article-title>. <source>Curr Oncol</source>
<year>2013</year>;<volume>20</volume>:<fpage>48</fpage>&#x02013;<lpage>61</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3747/co.20.1316">doi:10.3747/co.20.1316</ext-link><pub-id pub-id-type="pmid">23443928</pub-id></mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>S</given-names></name></person-group>
<article-title>Palbociclib: first global approval</article-title>. <source>Drugs</source>
<year>2015</year>;<volume>75</volume>:<fpage>543</fpage>&#x02013;<lpage>51</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s40265-015-0379-9">doi:10.1007/s40265-015-0379-9</ext-link><pub-id pub-id-type="pmid">25792301</pub-id></mixed-citation></ref><ref id="R86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>NC</given-names></name>, <name><surname>Ro</surname><given-names>J</given-names></name>, <name><surname>Andre</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Palbociclib in hormone-receptor-positive advanced breast cancer</article-title>. <source>N Engl J Med</source>
<year>2015</year>.</mixed-citation></ref><ref id="R87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dukelow</surname><given-names>T</given-names></name>, <name><surname>Kishan</surname><given-names>D</given-names></name>, <name><surname>Khasraw</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>CDK4/6 inhibitors in breast cancer</article-title>. <source>Anticancer Drugs</source>
<year>2015</year>;<volume>26</volume>:<fpage>797</fpage>&#x02013;<lpage>806</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CAD.0000000000000249">doi:10.1097/CAD.0000000000000249</ext-link><pub-id pub-id-type="pmid">26053278</pub-id></mixed-citation></ref><ref id="R88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huober</surname><given-names>J</given-names></name>, <name><surname>Fasching</surname><given-names>PA</given-names></name>, <name><surname>Barsoum</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer&#x02014;results of the eLEcTRA trial</article-title>. <source>Breast</source>
<year>2012</year>;<volume>21</volume>:<fpage>27</fpage>&#x02013;<lpage>33</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.breast.2011.07.006">doi:10.1016/j.breast.2011.07.006</ext-link><pub-id pub-id-type="pmid">21862331</pub-id></mixed-citation></ref><ref id="R89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumler</surname><given-names>I</given-names></name>, <name><surname>Nielsen</surname><given-names>DL</given-names></name></person-group>
<article-title>Trials of bevacizumab in breast cancer&#x02013;a safety review</article-title>. <source>Expert Opin Drug Saf</source>
<year>2012</year>;<volume>11</volume>(Suppl <issue>1</issue>):<fpage>S37</fpage>&#x02013;<lpage>48</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1517/14740338.2011.594038">doi:10.1517/14740338.2011.594038</ext-link><pub-id pub-id-type="pmid">21663533</pub-id></mixed-citation></ref><ref id="R90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>E</given-names></name>, <name><surname>Hiscox</surname><given-names>S</given-names></name></person-group>
<article-title>New therapeutic approaches in breast cancer</article-title>. <source>Maturitas</source>
<year>2011</year>;<volume>68</volume>:<fpage>121</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.maturitas.2010.10.012">doi:10.1016/j.maturitas.2010.10.012</ext-link><pub-id pub-id-type="pmid">21144683</pub-id></mixed-citation></ref><ref id="R91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Becerra</surname><given-names>R</given-names></name>, <name><surname>Santos</surname><given-names>N</given-names></name>, <name><surname>Diaz</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance</article-title>. <source>Int J Mol Sci</source>
<year>2012</year>;<volume>14</volume>:<fpage>108</fpage>&#x02013;<lpage>45</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/ijms14010108">doi:10.3390/ijms14010108</ext-link><pub-id pub-id-type="pmid">23344024</pub-id></mixed-citation></ref><ref id="R92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SR</given-names></name></person-group>
<article-title>New strategies in estrogen receptor-positive breast cancer</article-title>. <source>Clin Cancer Res</source>
<year>2010</year>;<volume>16</volume>:<fpage>1979</fpage>&#x02013;<lpage>87</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-09-1823">doi:10.1158/1078-0432.CCR-09-1823</ext-link><pub-id pub-id-type="pmid">20332324</pub-id></mixed-citation></ref><ref id="R93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>C</given-names></name>, <name><surname>Patten</surname><given-names>DK</given-names></name>, <name><surname>Januszewski</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Breast cancer: current and future endocrine therapies</article-title>. <source>Mol Cell Endocrinol</source>
<year>2014</year>;<volume>382</volume>:<fpage>695</fpage>&#x02013;<lpage>723</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mce.2013.08.001">doi:10.1016/j.mce.2013.08.001</ext-link><pub-id pub-id-type="pmid">23933149</pub-id></mixed-citation></ref><ref id="R94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>LA</given-names></name>, <name><surname>Perou</surname><given-names>CM</given-names></name></person-group>
<article-title>Palbociclib&#x02014;taking breast-cancer cells out of gear</article-title>. <source>N Engl J Med</source>
<year>2015</year>;<volume>373</volume>:<fpage>273</fpage>&#x02013;<lpage>4</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMe1506680">doi:10.1056/NEJMe1506680</ext-link><pub-id pub-id-type="pmid">26176385</pub-id></mixed-citation></ref></ref-list></back></article>